image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
212d6b325b34c178128fdcac9ba2738737eb0ce13083a2699dfd536749f95e93.png | complex | <table><tr><td></td><td>Group 1 (Critical DSS)</td><td>Group 2 (Relative DSS)</td><td>Group 3 (Non- DSS)</td><td><i>p</i>-value</td></tr><tr><td>Vertebral Levels</td><td>27</td><td>148</td><td>15</td><td></td></tr><tr><td rowspan="2">Gender</td><td>F: 11</td><td>F: 19</td><td>F: 4</td><td rowspan="2">0.65</td></tr><tr>... | <table><tr><td></td><td>Group 1 (Critical DSS)</td><td>Group 2 (Relative DSS)</td><td>Group 3 (Non- DSS)</td><td>p-value</td></tr><tr><td>Vertebral Levels</td><td>27</td><td>148</td><td>15</td><td></td></tr><tr><td rowspan="2">Gender</td><td>F: 11</td><td>F: 19</td><td>F: 4</td><td rowspan="2">0.65</td></tr><tr><td>M: ... | <table><tr><td></td><td>Group 1 (Critical DSS)</td><td>Group 2 (Relative DSS)</td><td>Group 3 (Non- DSS)</td><td>p-value</td></tr><tr><td>Mean Disc Height (mm (±SD))</td><td>10.4 (2.3)</td><td>9.9 (2.5)</td><td>9.7 (2.9)</td><td>0.58</td></tr><tr><td>BMI (±SD)</td><td>22.8 (2.3)</td><td>24.3 (3.2)</td><td>26.7 (3.7)</t... |
985e0088328a150db58b9968d379f629946e3a4993931d5b214e9063b0b2960e.png | simple | <table><tr><td>N level (kg ha<sup>−1</sup>)</td><td>Plant height (cm)</td><td>Productive tiller hill<sup>−1</sup></td><td>LAI</td><td>Days to maturity (d)</td><td>Number of spikelets panicle<sup>−1</sup></td><td>Fertility (%)</td><td>1000-grain weight (g)</td></tr><tr><td>0</td><td>96</td><td>8.6</td>... | <table><tr><td>N level (kg ha−1)</td><td>Plant height (cm)</td></tr><tr><td>0</td><td>96</td></tr><tr><td>100</td><td>100</td></tr><tr><td>125</td><td>103</td></tr><tr><td>150</td><td>106</td></tr><tr><td>175</td><td>106</td></tr><tr><td>200</td><td>108</td></tr><tr><td>LSD0.05</td><td>nsa</td></tr></table> | <table><tr><td>Productive tiller hill−1</td><td>LAI</td><td>Days to maturity (d)</td><td>Number of spikelets panicle−1</td><td>Fertility (%)</td><td>1000-grain weight (g)</td></tr><tr><td>8.6</td><td>4.6</td><td>105</td><td>83</td><td>89.6</td><td>24.6</td></tr><tr><td>9.1</td><td>5.2</td><td>108</td><td>111</td><td>85... |
b9bb6a3099a0d3d4ffb8b5e9fe1a9b78fc5648fd1384942f1947c54da477f063.png | simple | <table><tr><td></td><td>Soil EC</td><td>Nematode gall rating</td><td>P uptake</td><td>GY</td><td>RHL</td><td>RHD</td><td>DSW</td></tr><tr><td>Soil EC</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nematode gall rating</td><td>–0.07</td><td>1</td><td></td><td></td><td></td><td></t... | <table><tr><td></td><td>Soil EC</td><td>Nematode gall rating</td><td>P uptake</td><td>GY</td><td>RHL</td><td>RHD</td><td>DSW</td></tr><tr><td>Soil EC</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td>Nematode gall rating</td><td>–0.07</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P uptake</td><td>0.37***</td><td>0.03</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>GY</td><td>0.08</td><td>0.04</td><td>–0.22*</td><td>1</td><td></td><td></td><td></td></tr><tr><td... |
6f63db06addbddd8370be3d2be51b2052ca4a131ecb2f3e540035a818c4abf2c.png | simple | <table><tr><td>Characteristics</td><td>No. patients (%)</td><td>Median levels (interquartile range)</td><td><i>p</i></td></tr><tr><td>All patients</td><td>221 (100 %)</td><td>2.228 (0.416)</td><td></td></tr><tr><td>Age (years)</td><td></td><td></td><td>0.773<sup>a</sup></td></tr><tr><td>≤ 40</td><td>33 (14.9 %)</... | <table><tr><td>Characteristics</td><td>No. patients (%)</td><td>Median levels (interquartile range)</td><td>p</td></tr><tr><td>All patients</td><td>221 (100 %)</td><td>2.228 (0.416)</td><td></td></tr><tr><td>Age (years)</td><td></td><td></td><td>0.773a</td></tr><tr><td>≤ 40</td><td>33 (14.9 %)</td><td>2.160 (0.566)</td... | <table><tr><td>Characteristics</td><td>No. patients (%)</td><td>Median levels (interquartile range)</td><td>p</td></tr><tr><td>Postmenopausal</td><td>108 (48.9 %)</td><td>2.250 (0.379)</td><td></td></tr><tr><td>Tumor size</td><td></td><td></td><td>0.188a</td></tr><tr><td>pT1 (≤2 cm)</td><td>109 (49.3 %)</td><td>2.239 (... |
9ffce0699f8d86b67b47f0a8d0eb4430fcb419d3106322fe4154c9b765d149c9.png | complex | <table><tr><td>Disease stage</td><td colspan="3">Least-squared mean (SEM) spleen weight (mg)</td></tr><tr><td></td><td>Negative control (naïve + vehicle)</td><td>Positive control (EAE + vehicle)</td><td>Teriflunomide (EAE + treatment)</td></tr><tr><td>Onset</td><td>467.4 (21.5)</td><td>474.1 (18.5)</td><td>n/a</t... | <table><tr><td>Disease stage</td><td colspan="3">Least-squared mean (SEM) spleen weight (mg)</td></tr></table> | <table><tr><td></td><td>Negative control (naïve + vehicle)</td><td>Positive control (EAE + vehicle)</td><td>Teriflunomide (EAE + treatment)</td></tr><tr><td>Onset</td><td>467.4 (21.5)</td><td>474.1 (18.5)</td><td>n/a</td></tr><tr><td>Acute attack</td><td>464.8 (11.1)</td><td>347.6 (6.1)‡</td><td>395.0 (9.6)†</td></tr>... |
f9344027b6e3386f9e609711c3f2d4686cffd934c31a4f97c488a10170b673b1.png | simple | <table><tr><td>Characteristic</td><td>Frequency (%)</td></tr><tr><td>Age in yrs (mean ± SD)</td><td>80.6 ± 9.3</td></tr><tr><td>Race</td><td> </td></tr><tr><td> White</td><td>25 (49)</td></tr><tr><td> Black</td><td>23 (45)</td></tr><tr><td> Hispanic</td><td>3 (6)</td></tr><tr><td>Gender</td><td> </td></tr><tr... | <table><tr><td>Characteristic</td><td>Frequency (%)</td></tr><tr><td>Age in yrs (mean ± SD)</td><td>80.6 ± 9.3</td></tr><tr><td>Race</td><td></td></tr><tr><td>White</td><td>25 (49)</td></tr><tr><td>Black</td><td>23 (45)</td></tr><tr><td>Hispanic</td><td>3 (6)</td></tr><tr><td>Gender</td><td></td></tr><tr><td>Female</td... | <table><tr><td>Other</td><td>1 (2)</td></tr><tr><td>Hospital length of stay in days (mean ± SD)</td><td>6.1 ± 3.4</td></tr></table> |
5d932c8858716b023601b00c1fbdc782bdff43450d1e3c4057bd9c639b2e57d2.png | simple | <table><tr><td></td><td>Never-married</td><td>Married</td><td>Widowed</td><td>Divorced/separated</td></tr><tr><td>Men</td><td></td><td></td><td></td><td></td></tr><tr><td>Number of deaths from all causes</td><td>5325</td><td>19995</td><td>3321</td><td>6533</td></tr><tr><td>Number of deaths from all circulatory diseases... | <table><tr><td></td><td>Never-married</td><td>Married</td><td>Widowed</td></tr><tr><td>Men</td><td></td><td></td><td></td></tr><tr><td>Number of deaths from all causes</td><td>5325</td><td>19995</td><td>3321</td></tr><tr><td>Number of deaths from all circulatory diseases</td><td>1679</td><td>6031</td><td>1145</td></tr>... | <table><tr><td>Divorced/separated</td></tr><tr><td></td></tr><tr><td>6533</td></tr><tr><td>2025</td></tr><tr><td>406618</td></tr><tr><td></td></tr><tr><td>3938</td></tr><tr><td>829</td></tr><tr><td>447650</td></tr></table> |
cdd5122134cf2e9254e4470e36e7e517804b07b4b6450de6cd66c47bf18ec4fc.png | complex | <table><tr><td rowspan="2">Regulome DB score</td><td>(A)</td><td>(B)</td><td>(C)</td></tr><tr><td>No. of GWAS + LD SNPs (191482)</td><td>No. of (A) SNPs under VDR peaks (572)</td><td>No. of (B) SNPs under VDR peaks enriched for trait association (42)</td></tr><tr><td>1a</td><td>21</td><td>1</td><td>0</td></tr><tr><td>1... | <table><tr><td rowspan="2">Regulome DB score</td><td>(A)</td><td>(B)</td><td>(C)</td></tr><tr><td>No. of GWAS + LD SNPs (191482)</td><td>No. of (A) SNPs under VDR peaks (572)</td><td>No. of (B) SNPs under VDR peaks enriched for trait association (42)</td></tr><tr><td>1a</td><td>21</td><td>1</td><td>0</td></tr><tr><td>1... | <table><tr><td>1f</td><td>3182</td><td>43</td><td>5</td></tr><tr><td>2a</td><td>369</td><td>34</td><td>2</td></tr><tr><td>2b</td><td>3182</td><td>109</td><td>7</td></tr><tr><td>2c</td><td>137</td><td>8</td><td>0</td></tr><tr><td>Total</td><td>7324</td><td>213</td><td>15</td></tr></table> |
24dca732f936317e0540ce7adc15ed52f5f2c20e007af72acdd4e31be6dda01c.png | simple | <table><tr><td>Lamb</td><td>Weight (kg)</td><td>Age (days)</td><td>Total lavage (mL/kg)</td><td>CO<sub>tpud</sub> (mL/kg/min) initial–end</td><td>EVLWI<sub>tpud</sub> (mL/kg) initial</td><td>EVLWI<sub>tpud</sub> (mL/kg) end</td><td>EVLWI<sub>tpdd</sub> (mL/kg) initial</td><td>EVLWI<sub>tpdd</sub> (mL/kg) end</td>... | <table><tr><td>Lamb</td><td>Weight (kg)</td><td>Age (days)</td><td>Total lavage (mL/kg)</td><td>COtpud (mL/kg/min) initial–end</td><td>EVLWItpud (mL/kg) initial</td><td>EVLWItpud (mL/kg) end</td><td>EVLWItpdd (mL/kg) initial</td><td>EVLWItpdd (mL/kg) end</td><td>EVLWIgrav (mL/kg)</td><td>Final PEEP (mmHg)</td><td>Final... | <table><tr><td>2</td><td></td><td>1</td><td>3</td><td>254–66</td><td></td><td></td><td>12.3</td><td>NA</td><td>19.4</td><td></td><td>1.2</td></tr><tr><td>3</td><td>4.1</td><td>7</td><td>293</td><td>257–215</td><td>28.6</td><td>28.6</td><td>17.2</td><td>38.6</td><td>28.5</td><td>10</td><td>50.3</td></tr><tr><td>4</td><t... |
a0849a6b7ed12498cb59db01fc47fa9096f0bce16ae25a06fb62ce7118e65bf1.png | complex | <table><tr><td>Characteristics</td><td>Healthy donors (<i>n</i> = 68)</td><td>Patients (<i>n</i> = 109)</td></tr><tr><td>Age—years<sup>a</sup></td><td>32 (28–40)</td><td>37 (23–48)</td></tr><tr><td>Gender male—no. (%)</td><td>32 (47%)</td><td>38 (34.9%)</td></tr><tr><td>Caucasian race—%</t... | <table><tr><td>Characteristics</td><td>Healthy donors (n = 68)</td><td>Patients (n = 109)</td></tr><tr><td>Age—yearsa</td><td>32 (28–40)</td><td>37 (23–48)</td></tr><tr><td>Gender male—no. (%)</td><td>32 (47%)</td><td>38 (34.9%)</td></tr><tr><td>Caucasian race—%</td><td>100%</td><td>100%</td></tr><tr><td>Unrelated fami... | <table><tr><td>Characteristics</td><td>Healthy donors (n = 68)</td><td>Patients (n = 109)</td></tr><tr><td>Type II</td><td>NA</td><td>5 (4.5%)</td></tr><tr><td colspan="3">Prophylaxis—no. (%)</td></tr><tr><td>Tranexamic acid</td><td>NA</td><td>4 (3.8%)</td></tr><tr><td>Attenuated androgens</td><td>NA</td><td>15 (10%)</... |
1a270476bca73d58d866f80cf128cae7700eecc63271c1af4945278472d3dfc8.png | complex | <table><tr><td rowspan="2">Items</td><td colspan="6">Results of two–way repeated measures ANOVA</td></tr><tr><td>Variables</td><td>SS (Type III)</td><td>DF</td><td>MF</td><td>F</td><td>p-value</td></tr><tr><td rowspan="3">Systolic blood pressure (mmHg)</td><td>Time</td><td>3778.705</td><td>1</td><td>3778.705</td>... | <table><tr><td rowspan="2"></td><td colspan="6">Results of two–way repeated measures ANOVA</td></tr><tr><td>Va</td><td></td><td></td><td></td><td>F</td><td></td></tr></table> | <table><tr><td>Items</td><td>riables</td><td>SS (Type III)</td><td>DF</td><td>MF</td><td></td><td>p-value</td></tr><tr><td rowspan="3">Systolic blood pressure (mmHg)</td><td>Time</td><td>3778.705</td><td>1</td><td>3778.705</td><td>15.089</td><td><0.001</td></tr><tr><td>Time* like or dislike</td><td>0.250</td><td>1</td>... |
bbad9d98ac18ca1192416e5263f9f58e348729b398d2bc3c88602b534a67b76d.png | complex | <table><tr><td rowspan="2"></td><td colspan="4">RR interval expressions involved in QTc calculations</td><td colspan="3">Intra-subject comparison with individual QT/RR hysteresis</td></tr><tr><td>Individual hysteresis</td><td>Universal hysteresis</td><td>10 s RR average</td><td>3-interval RR average</td><td>Universal h... | <table><tr><td rowspan="2"></td><td colspan="4">RR interval expressions involved in QTc calculations</td><td colspan="3">Intra-subject comparison with individual QT/RR hysteresis</td></tr><tr><td>Individual hysteresis</td><td>Universal hysteresis</td><td>10 s RR average</td><td>3-interval RR average</td><td>Universal h... | <table><tr><td>QTc SD [ms]</td><td>5.49 ± 1.10</td><td>5.52 ± 1.11</td><td>10.49 ± 1.94</td><td>11.41 ± 2.11</td><td>0.03 ± 0.11</td><td>5.00 ± 1.51</td><td>5.92 ± 1.68</td></tr><tr><td>QTcL SD [ms]</td><td>5.67 ± 1.14</td><td>5.70 ± 1.15</td><td>10.68 ± 2.00</td><td>11.58 ± 2.17</td><td>0.02 ± 0.08</td><td>5.00 ± 1.52... |
805910aab729203a9bea225d0c0c59d1edd265af509f47a2981359c5131bdf76.png | simple | <table><tr><td>Facit-fatigue score</td><td>Mean (SE)*</td><td><i>P</i> change from pre-SBRT<sup>#</sup></td></tr><tr><td>Pre-SBRT</td><td>43.78 (1.43)</td><td>−</td></tr><tr><td>Post-SBRT (Month)</td></tr><tr><td> 1</td><td>40.66 (1.43)</td><td>0.02</td></tr><tr><td> 3</td><td>42.81 (1.43)</td><td>0.37</td></tr><... | <table><tr><td>Facit-fatigue score</td><td>Mean (SE)*</td><td>P change from pre-SBRT#</td></tr><tr><td>Pre-SBRT</td><td>43.78 (1.43)</td><td>−</td></tr><tr><td>Post-SBRT (Month)</td><td colspan="2"></td></tr></table> | <table><tr><td>1</td><td>40.66 (1.43)</td><td>0.02</td></tr><tr><td>3</td><td>42.81 (1.43)</td><td>0.37</td></tr><tr><td>6</td><td>43.07 (1.45)</td><td>0.87</td></tr><tr><td>9</td><td>41.13 (1.45)</td><td>0.40</td></tr><tr><td>12</td><td>43.18 (1.43)</td><td>0.61</td></tr></table> |
96fc6b9bf6d1dce2aeffc7ab43650cfa8704a8f3335587c1632210ea4356e0b9.png | complex | <table><tr><td colspan="2">Characteristics</td><td>Adjusted OR (95% CI)</td><td><i>p</i>-Value</td></tr><tr><td colspan="4">Age percentile (years)</td></tr><tr><td rowspan="5"></td><td>1–20 (18–46.9) </td><td>Reference</td><td></td></tr><tr><td>21–40 (47–59.9) </td><td>0.51 (0.18–1.39)</td... | <table><tr><td colspan="2">Characteristics</td><td>Adjusted OR (95% CI)</td><td>p-Value</td></tr><tr><td colspan="4">Age percentile (years)</td></tr><tr><td rowspan="5"></td><td>1–20 (18–46.9)</td><td>Reference</td><td></td></tr><tr><td>21–40 (47–59.9)</td><td>0.51 (0.18–1.39)</td><td>0.19</td></tr><tr><td>41–60 (60–66... | <table><tr><td rowspan="4"></td><td>High school equivalent of year 10 or lower</td><td>Reference</td><td></td></tr><tr><td>High school completion</td><td>1.15 (0.35–3.80)</td><td>0.82</td></tr><tr><td>Diploma or trade certificate</td><td>1.77 (0.74–4.25)</td><td>0.20</td></tr><tr><td>Bachelor’s or postgraduate degree</... |
3596bcbcbe24ddbfbe9bcc054b2436ee2ea424c2934104ab2373a4bccac960a5.png | complex | <table><tr><td rowspan="2">Author, year</td><td rowspan="2">Age at diagnosis</td><td colspan="5">Presentation</td><td rowspan="2">TSH receptor antibody</td><td rowspan="2">Cervical thyroidectomy before diagnosis struma ovarii</td><td rowspan="2">Prior pelvic exam that result negative</td><td rowspan="2">Ovarian scan be... | <table><tr><td rowspan="2">Author, year</td><td rowspan="2">Age at diagnosis</td><td colspan="5">Presentation</td><td rowspan="2">TSH receptor antibody</td><td rowspan="2">Cervical thyroidectomy before diagnosis struma ovarii</td><td rowspan="2">Prior pelvic exam that result negative</td><td rowspan="2">Ovarian scan be... | <table><tr><td rowspan="2">Author, year</td><td rowspan="2">Age at diagnosis</td><td colspan="5">Presentation</td><td rowspan="2">TSH receptor antibody</td><td rowspan="2">Cervical thyroidectomy before diagnosis struma ovarii</td><td rowspan="2">Prior pelvic exam that result negative</td><td rowspan="2">Ovarian scan be... |
c39ab9990cec49d6ecf88c2fb5f2c4f00c9a0745788892d2b55de7d51f1e3d05.png | complex | <table><tr><td colspan="4">Pif + VMY <i>vs</i>. VMY</td></tr><tr><td>Up-regulated</td><td>Fold</td><td>Down-regulated</td><td>Fold</td></tr><tr><td>EndoG</td><td>8.77809E+30</td><td>FIGF</td><td>−6.10476E+11</td></tr><tr><td>CIDEB</td><td>1.9687E+12</td><td>ANGPT4</td><td>−6.017072518</td></tr><tr><td>PRSS5... | <table><tr><td colspan="2">Pif + VMY vs. VMY</td></tr><tr><td>Up-regulated</td><td>Fold</td></tr><tr><td>EndoG</td><td>8.77809E+30</td></tr><tr><td>CIDEB</td><td>1.9687E+12</td></tr><tr><td>PRSS54</td><td>1299.03</td></tr><tr><td>BIK</td><td>19.44</td></tr><tr><td>MAP3K9</td><td>18.19</td></tr><tr><td>ERBB3</td><td>15.... | <table><tr><td colspan="2">Pif + VMY vs. VMY</td></tr><tr><td>Down-regulated</td><td>Fold</td></tr><tr><td>FIGF</td><td>−6.10476E+11</td></tr><tr><td>ANGPT4</td><td>−6.017072518</td></tr><tr><td>GSK3A</td><td>−5.35</td></tr><tr><td>INCA1</td><td>−5.18</td></tr><tr><td>TNFSF14</td><td>−4.01</td></tr><tr><td>GDF15</td><t... |
50d31aaa2d9a3ecc5f3e64d16c47188e442256e2610ca399b4dbbd210682d3eb.png | simple | <table><tr><td></td><td>Antenatal Survey (<i>n</i>=180)</td><td>Postnatal Survey (<i>n</i>=228)</td></tr><tr><td>Median age at participation (IQR)</td><td>27.4 years (24.8, 30.9)</td><td>28.3 years (24.8, 31.9)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td> Married</td><td>96/180 (53 %)</td><td>99/... | <table><tr><td></td><td>Antenatal Survey (n=180)</td></tr><tr><td>Median age at participation (IQR)</td><td>27.4 years (24.8, 30.9)</td></tr><tr><td>Marital status</td><td></td></tr><tr><td>Married</td><td>96/180 (53 %)</td></tr><tr><td>Cohabiting</td><td>50/180 (28 %)</td></tr><tr><td>Single</td><td>34/180 (19 %)</td>... | <table><tr><td>Postnatal Survey (n=228)</td></tr><tr><td>28.3 years (24.8, 31.9)</td></tr><tr><td></td></tr><tr><td>99/228 (43 %)</td></tr><tr><td>84/228 (37 %)</td></tr><tr><td>45/228 (20 %)</td></tr><tr><td>28/225 (12 %)</td></tr><tr><td></td></tr><tr><td>210/222 (95 %)</td></tr><tr><td>12/222 (5 %)</td></tr><tr><td>... |
0ff4c9673670280d46ca25fbd42bc82d83f78fbd69ef8dde42f24ea45efa46a3.png | complex | <table><tr><td rowspan="2">Thin Film</td><td colspan="2">C<sub>3</sub>H<sub>8</sub> (1 ppm)</td></tr><tr><td>T<sub>recovery</sub> (s)</td><td>T<sub>response</sub> (s)</td></tr><tr><td>CuO</td><td>20</td><td>12</td></tr><tr><td>Au:CuO</td><td>30</td><td>34</td></tr><tr><td>Ag:CuO</td><td>26</td><td>18</td></tr><tr><td>C... | <table><tr><td rowspan="2">Thin Film</td><td colspan="2">C3H8 (1 ppm)</td></tr><tr><td>Trecovery (s)</td><td>Tresponse (s)</td></tr><tr><td>CuO</td><td>20</td><td>12</td></tr><tr><td>Au:CuO</td><td>30</td><td>34</td></tr><tr><td>Ag:CuO</td><td>26</td><td>18</td></tr></table> | <table><tr><td></td><td></td><td></td></tr><tr><td>Cr:CuO</td><td>10</td><td>24</td></tr><tr><td>Pd:CuO</td><td>35</td><td>15</td></tr><tr><td>Pt:CuO</td><td>55</td><td>12</td></tr><tr><td>Sb:CuO</td><td>92</td><td>30</td></tr><tr><td>Si:CuO</td><td>150</td><td>100</td></tr></table> |
ba38fdf498a57824e7756faa1903b12f25f2c951ae853572bd8891738db48345.png | simple | <table><tr><td><i>Characteristic</i></td><td><i>Impaired</i><sup>†</sup><i>and Inadequate Reading Ability (S-TOFHLA < 16)</i><sup>‡</sup></td><td><i>Impaired</i><sup>†</sup><i>and Limited Reading Ability (S-TOFHLA < 23)</i><sup>‡</sup></td></tr><tr><td>Sensitivity (%)</td><td>67 (58, 76)</... | <table><tr><td>Characteristic</td><td>Impaired†and Inadequate Reading Ability (S-TOFHLA < 16)‡</td><td>Impaired†and Limited Reading Ability (S-TOFHLA < 23)‡</td></tr><tr><td>Sensitivity (%)</td><td>67 (58, 76)</td><td>54 (47, 61)</td></tr></table> | <table><tr><td>Specificity (%)</td><td>82 (80, 85)</td><td>83 (81, 86)</td></tr><tr><td>Positive Predictive Power</td><td>0.31 (0.25, 0.37)</td><td>0.40 (0.34, 0.47)</td></tr><tr><td>Negative Predictive Power</td><td>0.96 (0.94, 0.97)</td><td>0.90 (0.88, 0.92)</td></tr><tr><td>Likelihood Ratio Positive (LR +)</td><td>3... |
8f6310f73a45fd785132f25a1e789899942dcb392884555cbb0f631a04ca4cc6.png | complex | <table><tr><td rowspan="2">Subscales</td><td>Pretest</td><td>Posttest</td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Physical</td><td>55.5 (35.8)</td><td>53.5 (38.1)</td></tr><tr><td>Role</td><td>57.8 (32.4)</td><td>59.8 (28.6)</td></tr><tr><td>Bodily pain</td><td>59.0 (33.8)</td><td>61.0 (37.5)</td></tr... | <table><tr><td rowspan="2">Subscales</td></tr><tr></tr><tr><td>Physical</td></tr><tr><td>Role</td></tr><tr><td>Bodily pain</td></tr><tr><td>General health</td></tr><tr><td>Vitality</td></tr><tr><td>Social</td></tr><tr><td>Role/emotional</td></tr><tr><td>Mental health</td></tr><tr><td>PCS</td></tr><tr><td>MCS</td></tr><... | <table><tr><td>Pretest</td><td>Posttest</td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>55.5 (35.8)</td><td>53.5 (38.1)</td></tr><tr><td>57.8 (32.4)</td><td>59.8 (28.6)</td></tr><tr><td>59.0 (33.8)</td><td>61.0 (37.5)</td></tr><tr><td>49.0 (24.6)</td><td>49.8 (26.2)</td></tr><tr><td>48.5 (28.3)</td><td>46... |
2e8355ef7ad9437f216b772522d1ca6503eb678230bf8589e5453a9a2d8dad36.png | simple | <table><tr><td>Characteristics</td><td>Median kappa coefficient (range)</td></tr><tr><td>Characteristics day 1</td><td></td></tr><tr><td>Position of the pronuclei</td><td>0.74 (0.65-0.77)</td></tr><tr><td>Size of the pronuclei</td><td>0.44 (0.33-0.57)</td></tr><tr><td>Cytoplasmic halo</td><td>-0.34 (-0.62-0)</td></tr><... | <table><tr><td>Characteristics</td><td>Median kappa coefficient (range)</td></tr><tr><td>Characteristics day 1</td><td></td></tr><tr><td>Position of the pronuclei</td><td>0.74 (0.65-0.77)</td></tr><tr><td>Size of the pronuclei</td><td>0.44 (0.33-0.57)</td></tr><tr><td>Cytoplasmic halo</td><td>-0.34 (-0.62-0)</td></tr><... | <table><tr><td>Characteristics day 2</td><td></td></tr><tr><td>Number of blastomeres</td><td>0.82 (0.80-0.93)</td></tr><tr><td>Degree of fragmentation</td><td>0.58 (0.53-0.62)</td></tr><tr><td>Size of blastomeres</td><td>0.59 (0.48-0.62)</td></tr><tr><td>Characteristics day 3</td><td></td></tr><tr><td>Number of blastom... |
dd25ebd53846d3df96921e17709adb16ee841c7d93d78b37cea74c06d280063b.png | simple | <table><tr><td>Sample</td><td>D<sub>10</sub> (μm)</td><td>D<sub>50</sub> (μm)</td><td>D<sub>90</sub> (μm)</td><td>CI (%)</td></tr><tr><td>Untreated</td><td>8.39 ± 0.24 <sup>a</sup></td><td>23.43 ± 0.32 <sup>a</sup></td><td>54.50 ± 0.61 <sup>a</sup></td><td>56.29 ± 0.08 <sup>a</sup></t... | <table><tr><td>Sample</td><td>D10 (μm)</td><td>D50 (μm)</td><td>D90 (μm)</td><td>CI (%)</td></tr></table> | <table><tr><td>Untreated</td><td>8.39 ± 0.24 a</td><td>23.43 ± 0.32 a</td><td>54.50 ± 0.61 a</td><td>56.29 ± 0.08 a</td></tr><tr><td>MCC1.0 h</td><td>5.35 ± 0.02 b</td><td>15.90 ± 0.10 b</td><td>40.43 ± 0.78 c</td><td>47.89 ± 0.06 b</td></tr><tr><td>MCC2.0 h</td><td>4.36 ± 0.06 c</td><td>13.63 ± 0.21 c</td><td>40.40 ± ... |
0c874d20efa4c5e871f1aa7b428c1391c0b5ca06448c2c23af4940bb9c19fdd9.png | simple | <table><tr><td>Gene</td><td>Tissue</td><td><i>n</i></td><td>Effect size (se)</td><td><i>p</i> value</td></tr><tr><td><i>MRPS6</i></td><td>Aortic artery</td><td>197</td><td>0.15 (0.05)</td><td>3.5 × 10<sup>−3</sup></td></tr><tr><td><i>MRPS6</i></td><td>Coronary artery</td><td>118</td><td>0.14 (0.11)</td><td>0... | <table><tr><td>Gene</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>MRPS6</td></tr><tr><td>KCNE2</td></tr><tr><td>KCNE2</td></tr><tr><td>KCNE2</td></tr><tr><td>KCNE2</td></tr><tr><td>KCNE2</td></tr><tr><td>KCNE2</... | <table><tr><td>Tissue</td><td>n</td><td>Effect size (se)</td><td>p value</td></tr><tr><td>Aortic artery</td><td>197</td><td>0.15 (0.05)</td><td>3.5 × 10−3</td></tr><tr><td>Coronary artery</td><td>118</td><td>0.14 (0.11)</td><td>0.22</td></tr><tr><td>Tibial artery</td><td>285</td><td>0.15 (0.05)</td><td>1.8 × 10−3</td><... |
6fbf65fce39f8cdb70e8047057b0cb7eb9f772187ccbb6938883545090bded66.png | complex | <table><tr><td>Name of the test</td><td>Procedure</td><td>Results</td></tr><tr><td rowspan="2">Alkaloids</td><td>Mayer's test</td><td>+</td></tr><tr><td>Hager's test</td><td>+</td></tr><tr><td>Saponins</td><td>Froth test</td><td>−</td></tr><tr><td rowspan="2">Flavonoids</td><td>Shinoda's test</td><td>+</td></tr><... | <table><tr><td>Name of the test</td><td>Procedure</td><td>Results</td></tr><tr><td>Alkalo</td><td>Mayer's</td><td></td></tr></table> | <table><tr><td>Name of the test</td><td>Procedure</td><td>Results</td></tr><tr><td rowspan="2">ids</td><td> test</td><td>+</td></tr><tr><td>Hager's test</td><td>+</td></tr><tr><td>Saponins</td><td>Froth test</td><td>−</td></tr><tr><td rowspan="2">Flavonoids</td><td>Shinoda's test</td><td>+</td></tr><tr><td>Lead acetate... |
efc79fb6a556cbadf9416c59c2e649d5e7e492b6fa564ad2abf02096a527b1ff.png | simple | <table><tr><td>Environmental Samples</td><td>16S rRNA Positives (%)</td></tr><tr><td>Plant biofilms</td><td>12/18 (66.7 <sup>a</sup>)</td></tr><tr><td>Water filtrates</td><td>12/12 (100 <sup>a</sup>)</td></tr><tr><td>Plant detritus</td><td>8/15 (53.3 <sup>a</sup>)</td></tr><tr><td>Soils</td><td>8/15 (53.3 <sup>a</sup>)... | <table><tr><td>Environmental Samples</td><td>16S rRNA Positives (%)</td></tr><tr><td>Plant biofilms</td><td>12/18 (66.7 a)</td></tr><tr><td>Water filtrates</td><td>12/12 (100 a)</td></tr></table> | <table><tr><td>Plant detritus</td><td>8/15 (53.3 a)</td></tr><tr><td>Soils</td><td>8/15 (53.3 a)</td></tr></table> |
80bd802e97b26519715306f8f20491ec31374dd1297bf6cfde08fcd3d970b655.png | simple | <table><tr><td>Classification</td><td>Name of model</td></tr><tr><td>Peripheral NP</td><td>Neuroma model</td></tr><tr><td></td><td>Chronic constriction injury model (CCI)</td></tr><tr><td></td><td>Partial sciatic nerve ligation model (PSL or Seltzer</td></tr><tr><td></td><td>model)</td></tr><tr><td></td><td>L5/L6 spina... | <table><tr><td>Classification</td><td>Name of model</td></tr><tr><td>Peripheral NP</td><td>Neuroma model</td></tr><tr><td></td><td>Chronic constriction injury model (CCI)</td></tr><tr><td></td><td>Partial sciatic nerve ligation model (PSL or Seltzer</td></tr><tr><td></td><td>model)</td></tr><tr><td></td><td>L5/L6 spina... | <table><tr><td>Classification</td><td>Name of model</td></tr><tr><td></td><td>Sciatic inflammatory neuritis model (SIN)</td></tr><tr><td></td><td>Postherpetic neuralgia model (PHN)</td></tr><tr><td></td><td>Diabetic neuropathic pain model</td></tr><tr><td></td><td>Drugs-induced peripheral neuropathy model</td></tr><tr>... |
fc0d93087331ac40b299a5125d22841add004b0e437801281235ae468d2f0073.png | complex | <table><tr><td rowspan="2">SNP ID</td><td rowspan="2">Model</td><td rowspan="2">Genotype</td><td colspan="3">Gastric cancer</td><td colspan="3">Colorectal cancer</td></tr><tr><td colspan="2">OR (95 % CI)</td><td><i>P</i> value</td><td colspan="2">OR (95 % CI)</td><td><i>P</i> value</td></tr><tr><td>rs10795668</td><td>A... | <table><tr><td rowspan="2">SNP ID</td><td rowspan="2">Model</td><td rowspan="2">Genotype</td><td colspan="3">Gastric cancer</td><td colspan="3">Colorectal cancer</td></tr><tr><td colspan="2">OR (95 % CI)</td><td>P value</td><td colspan="2">OR (95 % CI)</td><td>P value</td></tr><tr><td>rs10795668</td><td>Allele model</t... | <table><tr><td rowspan="2">SNP ID</td><td rowspan="2">Model</td><td rowspan="2">Genotype</td><td colspan="3">Gastric cancer</td><td colspan="3">Colorectal cancer</td></tr><tr><td colspan="2">OR (95 % CI)</td><td>P value</td><td colspan="2">OR (95 % CI)</td><td>P value</td></tr><tr><td>824999</td><td>e model</td><td>C/A... |
b2d99daf2b609439d6ba5ac9ff58b332385d6f7f56fd9dd169422df5b09f96bb.png | complex | <table><tr><td rowspan="2" colspan="2">P<sub>C</sub> (%)</td><td colspan="7">Δb<sub>x</sub></td></tr><tr><td>−3km</td><td>−2km</td><td>−1km</td><td>0km</td><td>1km</td><td>2km</td><td>3km</td></tr><tr><td rowspan="7">Δ<i>b<sub>y</sub></i></td><td>-3 km</td><td>96.87</td><td>97.16</td><td>96.... | <table><tr><td rowspan="2" colspan="2">PC (%)</td><td colspan="7">Δbx</td></tr><tr><td>−3km</td><td>−2km</td><td>−1km</td><td>0km</td><td>1km</td><td>2km</td><td>3km</td></tr><tr><td rowspan="6">Δby</td><td>-3 km</td><td>96.87</td><td>97.16</td><td>96.63</td><td>97.23</td><td>97.48</td><td>97.55</td><td>97.09</td></tr>... | <table><tr><td rowspan="2" colspan="2">PC (%)</td><td colspan="7">Δbx</td></tr><tr><td>−3km</td><td>−2km</td><td>−1km</td><td>0km</td><td>1km</td><td>2km</td><td>3km</td></tr><tr><td>Δby</td><td>3 km</td><td>97.26</td><td>97.08</td><td>97.28</td><td>96.88</td><td>97.19</td><td>97.17</td><td>97.11</td></tr></table> |
bfdfb324f51f3912f5670deb809e6588897d1bec47e3d681f437956ab595e4e6.png | simple | <table><tr><td></td><td>Control(n=8)</td><td>NE(n=8)</td></tr><tr><td> Body </td><td> 40.4±1.84 </td><td> 36.4±1.28* </td></tr><tr><td> Brain </td><td> 1.31±0.11 </td><td> 1.27±0.08 NS </td></tr><tr><td> Cerebellum </td><td> 0.164±0.010 </td><td> 0.155±0.012 NS </td></tr></table> | <table><tr><td></td><td>Control(n=8)</td><td>NE(n=8)</td></tr><tr><td>Body</td><td>40.4±1.84</td><td>36.4±1.28*</td></tr><tr><td>Brain</td><td>1.31±0.11</td><td>1.27±0.08 NS</td></tr></table> | <table><tr><td></td><td>Control(n=8)</td><td>NE(n=8)</td></tr><tr><td>Cerebellum</td><td>0.164±0.010</td><td>0.155±0.012 NS</td></tr></table> |
f6742cc9690517a6cb8afedc9b2feaaba4ab800769d5f96df05c71c3db38e464.png | complex | <table><tr><td></td><td colspan="3">Wild-Type Sibling</td><td colspan="4">Mutant</td></tr><tr><td>Gene</td><td>Control</td><td>200 μM Neomycin</td><td>% HCs Remaining</td><td colspan="2">Control</td><td>200 μM Neomycin</td><td>% HCs Remaining</td></tr><tr><td>Ciliary axoneme and intraflagellar transport</td><... | <table><tr><td></td><td colspan="3">Wild-Type Sibling</td><td colspan="2">Mutant</td></tr><tr><td>Gene</td><td>Control</td><td>200 μM Neomycin</td><td>% HCs Remaining</td><td colspan="2">Control</td></tr><tr><td>Ciliary axoneme and intraflagellar transport</td><td></td><td></td><td></td><td colspan="2"></td></tr><tr><t... | <table><tr><td colspan="2">Mutant</td></tr><tr><td>200 μM Neomycin</td><td>% HCs Remaining</td></tr><tr><td></td><td></td></tr><tr><td>5.63 ± 1.26</td><td rowspan="2">65.13</td></tr><tr><td>P < 0.0001</td></tr><tr><td>6.17 ± 1.41</td><td rowspan="2">61.89</td></tr><tr><td>P < 0.0001</td></tr><tr><td>4.43 ± 1.70</td><td... |
9fe2ed6c901b68f7a3ba4968f80b05231ec694b04aa79e3e8700f0a28f94d9fc.png | simple | <table><tr><td>Antimicrobial resistance pattern</td><td><i>S. flexneri</i> (6)</td><td><i>S. dysenteriae</i> (4)</td><td><i>S. boydii</i> (2)</td></tr><tr><td>AMP-AMC-CHL-CMX-STR</td><td>1(16.7)</td><td></td><td></td></tr><tr><td>AMP-CHL-CMX-STR-TET</td><td>1(16.7)</td><td>1(25)</td><td>2(100)</td></tr><tr><td>AMP-CHL-... | <table><tr><td>Antimicrobial resistance pattern</td><td>S. flexneri (6)</td><td>S. dysenteriae (4)</td><td>S. boydii (2)</td></tr><tr><td>AMP-AMC-CHL-CMX-STR</td><td>1(16.7)</td><td></td><td></td></tr><tr><td>AMP-CHL-CMX-STR-TET</td><td>1(16.7)</td><td>1(25)</td><td>2(100)</td></tr></table> | <table><tr><td>Antimicrobial resistance pattern</td><td>S. flexneri (6)</td><td>S. dysenteriae (4)</td></tr><tr><td>AMP-CHL-CMX-STR</td><td>3(50)</td><td>1(75)</td></tr><tr><td>AMP-CHL-CMX</td><td>1(16.7)</td><td></td></tr></table> |
71f06025e45a5bb66cc0a14778fb31efc430eed6768ea876472efb1150fbba2f.png | complex | <table><tr><td rowspan="2">Pretreatment</td><td colspan="4">Sample Point</td><td>Total Isolates</td></tr><tr><td>Point 1</td><td>Point 2</td><td>Point 3</td><td>Point 4</td><td></td></tr><tr><td>S</td><td>35/5</td><td>55/0</td><td>22/0</td><td>47/4</td><td>159/9</td></tr><tr><td>C</td><td>34/6</td><td>34/2</td><td>36/1... | <table><tr><td rowspan="2">Pretreatment</td><td colspan="4">Sample Point</td><td>Total Isolates</td></tr><tr><td>Point 1</td><td>Point 2</td><td>Point 3</td><td>Point 4</td><td></td></tr><tr><td>S</td><td>35/5</td><td>55/0</td><td>22/0</td><td>47/4</td><td>159/9</td></tr><tr><td>C</td><td>34/6</td><td>34/2</td><td>36/1... | <table><tr><td rowspan="2">Pretreatment</td><td colspan="4">Sample Point</td><td>Total Isolates</td></tr><tr><td>Point 1</td><td>Point 2</td><td>Point 3</td><td>Point 4</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>11/1</td><td>21/1</td></tr><tr><td rowspan="2">Total Isolates</td><td rowspan="2">214/44<... |
f4be14148be9bafa5d7b56d8b268b4d255d923c39023512deaee444d6e516b70.png | simple | <table><tr><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td></tr><tr><td><i>Enterobacter sakazakii</i></td><td>35</td><td>ATCC 29544 (CIP)</td><td><i>Salmonella </i>Hadar</td><td>2</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>CIP 104951 (C... | <table><tr><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td></tr><tr><td>Enterobacter sakazakii</td><td>35</td><td>ATCC 29544 (CIP)</td><td>Salmonella Hadar</td><td>2</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>CIP 104951 (CIP)</td><td>Sa... | <table><tr><td>Buttiauxella agrestis</td><td>1</td><td>(AFSSA)</td><td>Listeria ivanovii</td><td>1</td><td>Clip 74915 (CIP)</td></tr><tr><td>Hafnia alvei</td><td>5</td><td>(AFSSA)</td><td>Enterococcus faecalis</td><td>2</td><td>(AFSSA)</td></tr><tr><td>Klebsiella pneumoniae</td><td>8</td><td>ATCC 13883</td><td>Enteroco... |
dcd26f6829151b579f32478cdd669690ed8b0176840cab44b97b43a585d24b0d.png | simple | <table><tr><td>Trait</td><td>Day 0</td><td>Day 1</td><td>Day 3</td><td>Day 7</td><td><i>P</i></td></tr><tr><td>pH</td><td>6.43 (0.20)<sup>#</sup></td><td>5.55 (0.13)</td><td>-</td><td>-</td><td> </td></tr><tr><td>Conductivity</td><td>-</td><td>6.50 (3.05)</td><td>10.75 (2.65)</td><td>11.55 (2.44)</td><td>0.10</td></tr>... | <table><tr><td>Trait</td><td>Day 0</td><td>Day 1</td><td>Day 3</td><td>Day 7</td><td>P</td></tr><tr><td>pH</td><td>6.43 (0.20)#</td><td>5.55 (0.13)</td><td>-</td><td>-</td><td></td></tr><tr><td>Conductivity</td><td>-</td><td>6.50 (3.05)</td><td>10.75 (2.65)</td><td>11.55 (2.44)</td><td>0.10</td></tr></table> | <table><tr><td>CIE L*</td><td>-</td><td>55.42 (2.01)</td><td>54.80 (2.62)</td><td>54.43 (3.95)</td><td>0.73</td></tr><tr><td>CIE a*</td><td>-</td><td>7.32 (0.67)</td><td>9.63 (3.71)</td><td>9.34 (2.08)</td><td>0.27</td></tr><tr><td>CIE b*</td><td>-</td><td>15.43 (0.48)a</td><td>15.53 (0.46)a</td><td>16.74 (1.12)b</td><... |
409fb7810a77c57dda8714050ed70b1c5540400c34ccc67b52f2ceaebfc65435.png | simple | <table><tr><td>Classification</td><td>Mutations and Relative Frequency</td></tr><tr><td>Congenital nevi</td><td>NRAS > BRAF</td></tr><tr><td>Spitz nevi</td><td>HRAS > BRAF > NRAS</td></tr><tr><td>Acquired nevi</td><td>BRAF > NRAS</td></tr><tr><td>Blue nevi</td><td>GNAQ > BRAF</td></tr></table> | <table><tr><td>Classification</td><td>Mutations and Relative Frequency</td></tr><tr><td>Congenital nevi</td><td>NRAS > BRAF</td></tr></table> | <table><tr><td>Classification</td><td>Mutations and Relative Frequency</td></tr><tr><td>Spitz nevi</td><td>HRAS > BRAF > NRAS</td></tr><tr><td>Acquired nevi</td><td>BRAF > NRAS</td></tr><tr><td>Blue nevi</td><td>GNAQ > BRAF</td></tr></table> |
48414eedc924cdbd35f3bf44c6c77cb4eaa9b468d446e63faf238a3a1b025965.png | complex | <table><tr><td>Variables</td><td>Mean</td><td>Std. Dev.</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">Health outcome variables for men</td></tr><tr><td> Diabetes rate (%)</td><td>2.11</td><td>2.34</td><td>0.00</td><td>14.36</td></tr><tr><td> Obesity rate (%)</td><td>11.45</td><td>7.92</td><td>1.10</td><td>36.73<... | <table><tr><td>Variables</td><td>Mean</td><td>Std. Dev.</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">Health outcome variables for men</td></tr><tr><td>Diabetes rate (%)</td><td>2.11</td><td>2.34</td><td>0.00</td><td>14.36</td></tr></table> | <table><tr><td>Obesity rate (%)</td><td>11.45</td><td>7.92</td><td>1.10</td><td>36.73</td></tr><tr><td>Hypertension rate (%)</td><td>24.18</td><td>9.46</td><td>7.99</td><td>46.20</td></tr><tr><td>Average age</td><td>44.86</td><td>3.42</td><td>37.76</td><td>55.24</td></tr><tr><td colspan="5">Health outcome variables for... |
7a86c306dc8b853df7626ee288d011edba65ef54622aff7fd6c3606352ae49ad.png | complex | <table><tr><td rowspan="3">Characteristic</td><td rowspan="3">No.</td><td colspan="3">RECQL protein expression</td><td colspan="2"></td></tr><tr><td colspan="2">Low</td><td colspan="2">High</td><td rowspan="2">p</td></tr><tr><td>No.</td><td>%</td><td>No.</td><td>%</td></tr><tr><td>Total</td><td>322</td><td>133</td><td>... | <table><tr><td rowspan="3">Characteristic</td><td rowspan="3">No.</td><td colspan="3">RECQL protein expression</td><td colspan="2"></td></tr><tr><td colspan="2">Low</td><td colspan="2">High</td><td rowspan="2">p</td></tr><tr><td>No.</td><td>%</td><td>No.</td><td>%</td></tr><tr><td>Total</td><td>322</td><td>133</td><td>... | <table><tr><td rowspan="3">Characteristic</td><td rowspan="3">No.</td><td colspan="3">RECQL protein expression</td><td colspan="2"></td></tr><tr><td colspan="2">Low</td><td colspan="2">High</td><td rowspan="2">p</td></tr><tr><td>No.</td><td>%</td><td>No.</td><td>%</td></tr><tr><td>No therapy</td><td>31</td><td>12</td><... |
945f5f980cff81c80542eae37bb3937a30b62e87eedb83ebe777e9dd7babdc3b.png | complex | <table><tr><td></td><td colspan="3">Before multiple imputation</td><td colspan="3">After multiple imputation</td></tr><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Intercept</td><td>0.05 (0.02)‡</td><td>0.02 (0.01)‡</td><td>0.01 (0.... | <table><tr><td></td><td colspan="3">Before multiple imputation</td><td colspan="3">After multiple imputation</td></tr><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Intercept</td><td>0.05 (0.02)‡</td><td>0.02 (0.01)‡</td><td>0.01 (0.01)‡</td><td... | <table><tr><td></td><td colspan="3">Before multiple imputation</td><td colspan="3">After multiple imputation</td></tr><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>District-level variables</td><td></td><td></td><td></td><td></td><td></td><td></... |
c9bc985a9882c6d25d7c4615247bba759b1c02e327a55d1583a6551c63e1eec5.png | complex | <table><tr><td>Demographic characteristic</td><td>Frequency</td><td>%</td></tr><tr><td colspan="3">Campus location</td></tr><tr><td>Site 1</td><td>47</td><td>18.7</td></tr><tr><td>Site 2</td><td>205</td><td>81.3</td></tr><tr><td colspan="3">Year of study</td></tr><tr><td>Year 2</td><td>184</td><td>74.5</td></tr><tr><td... | <table><tr><td>Demographic characteristic</td><td>Frequency</td></tr><tr><td colspan="2">Campus location</td></tr><tr><td>Site 1</td><td>47</td></tr><tr><td>Site 2</td><td>205</td></tr><tr><td colspan="2">Year of study</td></tr><tr><td>Year 2</td><td>184</td></tr><tr><td>Year 3</td><td>43</td></tr><tr><td>Year 4</td><t... | <table><tr><td>%</td></tr><tr><td>Campus location</td></tr><tr><td>18.7</td></tr><tr><td>81.3</td></tr><tr><td>Year of study</td></tr><tr><td>74.5</td></tr><tr><td>17.4</td></tr><tr><td>6.5</td></tr><tr><td>Gender</td></tr><tr><td>91.3</td></tr><tr><td>8.7</td></tr><tr><td>Marital status</td></tr><tr><td>82.0</td></tr>... |
c1267daf8ddab1e498525cd25d1800dbf1bf8c92ed6c183fd77caeb29595f832.png | complex | <table><tr><td></td><td colspan="3">Based on Annual Mileage: Magnusson and Colleagues [32]</td><td colspan="3">Based on Tyres Sold: Swedish National Chemicals Inspectorate [33]</td></tr><tr><td></td><td>Wear mg/km</td><td>Total Mileage in 2012 (×10<sup>6</sup> km)</td><td>Total Wear 2012 Tonnes/Year</td><td>Mass o... | <table><tr><td></td><td colspan="3">Based on Annual Mileage: Magnusson and Colleagues [32]</td></tr><tr><td></td><td>Wear mg/km</td><td>Total Mileage in 2012 (×106 km)</td><td>Total Wear 2012 Tonnes/Year</td></tr><tr><td>Passenger car</td><td>50</td><td>62,940</td><td>3147</td></tr><tr><td>Bus/lorry</td><td>700</td><td... | <table><tr><td colspan="3">Based on Tyres Sold: Swedish National Chemicals Inspectorate [33]</td></tr><tr><td>Mass of Tyres Consumed Annually kg</td><td>Weight Loss (17%) kg</td><td>Total Wear 2002 tonnes/year</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>60,000,000</td><td>10... |
24b71e032d3b00092fb2aa70b0aa1fb0d02727f48501ad4d161284e5aa174d0b.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="5">Often<sup>a</sup></td></tr><tr><td>n</td><td>%</td><td>OR crude</td><td>95% CI</td><td><i>p</i></td></tr><tr><td colspan="6">Self-rated health</td></tr><tr><td> Good/very good</td><td>387</td><td>18.3</td><td>1.00</td><td></td><td rowspan="3"><0.001</td>... | <table><tr><td rowspan="2">Characteristics</td><td colspan="5">Oftena</td></tr><tr><td>n</td><td>%</td><td>OR crude</td><td>95% CI</td><td>p</td></tr><tr><td colspan="6">Self-rated health</td></tr><tr><td>Good/very good</td><td>387</td><td>18.3</td><td>1.00</td><td></td><td rowspan="3"><0.001</td></tr><tr><td>Regular</... | <table><tr><td rowspan="2">Characteristics</td><td colspan="5">Oftena</td></tr><tr><td>n</td><td>%</td><td>OR crude</td><td>95% CI</td><td>p</td></tr><tr><td>None</td><td>358</td><td>20.8</td><td>1.00</td><td></td><td rowspan="3">0.116</td></tr><tr><td>Up to 9 days</td><td>200</td><td>22.6</td><td>1.11</td><td>(0.91–1.... |
1e6c472ce0d642afa38952a3035e2640d74a0af860ed8f2a1a31fac275477079.png | complex | <table><tr><td>Host</td><td colspan="2">Demographic factor</td><td>Positive animals percentage</td></tr><tr><td rowspan="7">Sheep (<i>n</i> = 189)</td><td rowspan="2">Gender</td><td>Male (128)</td><td>66 (34.9%)<sup>a</sup></td></tr><tr><td>Female (61)</td><td>20 (10.6%)</td></tr><tr><td rowspan="3">Age</td><td>Group I... | <table><tr><td>Host</td><td colspan="2">Demographic factor</td><td>Positive animals percentage</td></tr></table> | <table><tr><td rowspan="7">Sheep (n = 189)</td><td rowspan="2">Gender</td><td>Male (128)</td><td>66 (34.9%)a</td></tr><tr><td>Female (61)</td><td>20 (10.6%)</td></tr><tr><td rowspan="3">Age</td><td>Group I (84)</td><td>47 (24.9%)a</td></tr><tr><td>Group II (89)</td><td>36 (19.0%)</td></tr><tr><td>Group III (16)</td><td... |
1c59324695140871eae050efc17b3c7741e1e8ddd79338e68d6e62fed1081c8a.png | complex | <table><tr><td>Items</td><td>Group</td><td>Villus Height (μm)</td><td>Crypt Depth (μm)</td><td>Villus Height/Crypt Depth</td></tr><tr><td rowspan="2">Jejunum</td><td>Control</td><td>1212.27 ± 47.79 <sup>a</sup></td><td>249.78 ± 12.50 <sup>a</sup></td><td>4.86 ± 0.29</td></tr><tr><td>200 mg/kg</... | <table><tr><td>Items</td><td>Group</td><td>Villus Height (μm)</td></tr><tr><td rowspan="2">Jejunum</td><td>Control</td><td>1212.27 ± 47.79 a</td></tr><tr><td>200 mg/kg</td><td>1381.83 ± 36.21 b</td></tr><tr><td rowspan="2">Ileum</td><td>Control</td><td>1175.01 ± 59.35 a</td></tr><tr><td>200 mg/kg</td><td>1417.10 ± 75.1... | <table><tr><td>Crypt Depth (μm)</td><td>Villus Height/Crypt Depth</td></tr><tr><td>249.78 ± 12.50 a</td><td>4.86 ± 0.29</td></tr><tr><td>370.41 ± 10.03 b</td><td>3.69 ± 0.37</td></tr><tr><td>213.96 ± 33.02 a</td><td>5.58 ± 0.56</td></tr><tr><td>411.05 ± 45.39 b</td><td>3.49 ± 0.51</td></tr></table> |
ca02c6c27ec5cf2a33f894779cbe3d2892fef7b69faaff93ef7cd6d620267a14.png | simple | <table><tr><td> </td><td>StudypopulationN=79</td><td>Aggressivesubjectsn=31</td><td>Non-aggressivesubjectsn=48</td><td>Significancep</td></tr><tr><td>Mean age </td><td>82.7±8.7</td><td>80.2±11.2</td><td>84.4±6.2</td><td>0.1</td></tr><tr><td>Sex (% female)</td><td>50 (63.3)</td><td>14 (45.2)</td><td>36 (7... | <table><tr><td></td><td>StudypopulationN=79</td></tr><tr><td>Mean age</td><td>82.7±8.7</td></tr><tr><td>Sex (% female)</td><td>50 (63.3)</td></tr><tr><td>Marital status (% living alone)</td><td>50 (63.3)</td></tr><tr><td>MMSE mean±SD</td><td>17.9±7.1</td></tr><tr><td>CMAI mean±SD</td><td>46.2±22.1</td></tr><tr><td>F-RA... | <table><tr><td>Aggressivesubjectsn=31</td><td>Non-aggressivesubjectsn=48</td><td>Significancep</td></tr><tr><td>80.2±11.2</td><td>84.4±6.2</td><td>0.1</td></tr><tr><td>14 (45.2)</td><td>36 (75.0)</td><td>0.01</td></tr><tr><td>15 (48.4)</td><td>35 (72.9)</td><td>0.028</td></tr><tr><td>15.13±7.8</td><td>19.7±5.9</td><td>... |
f16891bc4c078c0cc84495e7a375827894d84f4d4b364bed04cdd8d72a67b361.png | simple | <table><tr><td></td><td>RA with MAC-PD</td><td>RA without MAC-PD</td><td>Total</td></tr><tr><td>Anti-GPL ab, positive</td><td>8</td><td>4</td><td>12</td></tr><tr><td>Anti-GPL ab, negative</td><td>2</td><td>355</td><td>357</td></tr><tr><td>Total</td><td>10</td><td>359</td><td>369</td></tr></table> | <table><tr><td></td><td>RA with MAC-PD</td><td>RA without MAC-PD</td><td>Total</td></tr><tr><td>Anti-GPL ab, positive</td><td>8</td><td>4</td><td>12</td></tr></table> | <table><tr><td></td><td>RA with MAC-PD</td><td>RA without MAC-PD</td><td>Total</td></tr><tr><td>Anti-GPL ab, negative</td><td>2</td><td>355</td><td>357</td></tr><tr><td>Total</td><td>10</td><td>359</td><td>369</td></tr></table> |
9b3530435cae09217a0b1fef3f363b4d037e413312d6c7d43bf00a86c3877676.png | complex | <table><tr><td rowspan="2">Emergency level</td><td rowspan="2">No.</td><td>Admitted to</td><td>Admission risk,</td></tr><tr><td>hospital</td><td>% (95% CI)</td></tr><tr><td>A</td><td>28,630</td><td>18,440</td><td>64.4 (63.8-65.0)</td></tr><tr><td>B</td><td>25,419</td><td>13,190</td><td>51.9 (51.3-52.5)</td></tr><tr><td... | <table><tr><td>Emergency level</td><td>No.</td><td>Admitted to</td><td>Admission risk,</td></tr></table> | <table><tr><td>Emergency level</td><td>No.</td><td>hospital</td><td>% (95% CI)</td></tr><tr><td>A</td><td>28,630</td><td>18,440</td><td>64.4 (63.8-65.0)</td></tr><tr><td>B</td><td>25,419</td><td>13,190</td><td>51.9 (51.3-52.5)</td></tr><tr><td>C</td><td>1,112</td><td>475</td><td>42.7 (39.8-45.7)</td></tr><tr><td>D</td>... |
8e6dc7aa8085a07a1f4947ee2a54a3f1206cf0b47469a906ba2f661ab1aed65a.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td>t-Statistic</td><td>p-value</td></tr><tr><td>C</td><td>0.912</td><td>9.44</td><td>0.000</td></tr><tr><td>AGE</td><td>1.78E-05</td><td>0.009</td><td>0.993</td></tr><tr><td>EDU</td><td>0.034</td><td>1.030</td><td>0.307</td></tr><tr><td>OCC</td><td>0.025</td><td>0.706</t... | <table><tr><td>Variable</td><td>Coefficient</td><td>t-Statistic</td><td>p-value</td></tr><tr><td>C</td><td>0.912</td><td>9.44</td><td>0.000</td></tr><tr><td>AGE</td><td>1.78E-05</td><td>0.009</td><td>0.993</td></tr><tr><td>EDU</td><td>0.034</td><td>1.030</td><td>0.307</td></tr><tr><td>OCC</td><td>0.025</td><td>0.706</t... | <table><tr><td>MS</td><td>0.013</td><td>0.387</td><td>0.700</td></tr><tr><td>INC</td><td>1.40E-07</td><td>0.238</td><td>0.813</td></tr></table> |
3a341b1aa093c8b8cdaa634d2c526e92b45924be2f9ae9554dd82703d2783581.png | simple | <table><tr><td>Patient Number</td><td>Age</td><td>Gender</td><td>Tumour location</td><td>Initial MRI Dimensions (cm)</td><td>PTV volume (cm<sup>3</sup>)</td></tr><tr><td>1</td><td>29</td><td>F</td><td>L anterior chest wall</td><td>6.5 × 3.6 × 2.1</td><td>534</td></tr><tr><td>2</td><td>47</td><td>M</td><td>R p... | <table><tr><td>Patient Number</td><td>Age</td><td>Gender</td><td>Tumour location</td><td>Initial MRI Dimensions (cm)</td><td>PTV volume (cm3)</td></tr><tr><td>1</td><td>29</td><td>F</td><td>L anterior chest wall</td><td>6.5 × 3.6 × 2.1</td><td>534</td></tr><tr><td>2</td><td>47</td><td>M</td><td>R posterior chest wall</... | <table><tr><td>10</td><td>20</td><td>M</td><td>L neck and supraclavicular fossa</td><td>8.7 × 5.5 × 6.7</td><td>646</td></tr></table> |
766ead4dd05c963aa5ef900c8617dddcdae0f65ed0f98971ce4320ff6238ff02.png | simple | <table><tr><td>Site</td><td>Treatment</td><td>IRR (95%CI)</td><td>P value</td></tr><tr><td>Kilifi</td><td>Carbon dioxide only</td><td>0.57(0.21 – 1.52)</td><td>0.255</td></tr><tr><td>Kilifi</td><td>Blend 2</td><td>1.33 (0.50 -3.57)</td><td>0.552</td></tr><tr><td>Kilifi</td><td>Blend 4</td><td>0.95(0.36- 2.56)</td... | <table><tr><td>Site</td><td>Treatment</td><td>IRR (95%CI)</td><td>P value</td></tr></table> | <table><tr><td>Kilifi</td><td>Carbon dioxide only</td><td>0.57(0.21 – 1.52)</td><td>0.255</td></tr><tr><td>Kilifi</td><td>Blend 2</td><td>1.33 (0.50 -3.57)</td><td>0.552</td></tr><tr><td>Kilifi</td><td>Blend 4</td><td>0.95(0.36- 2.56)</td><td>0.931</td></tr><tr><td>Kilifi</td><td>Hexanoic acid</td><td>2.2 (0.82- 5.87)<... |
47641d4f3922ab355438c36cf7b0de5d858a3f523b86d6b832078c898352f155.png | simple | <table><tr><td></td><td></td><td>Mean</td><td>SD</td><td>No.</td><td>p-value</td></tr><tr><td>Items from CAD and renal failure (lecture format the same for each group)</td><td>Live lecture</td><td>4.42</td><td>1.08</td><td>12</td><td></td></tr><tr><td></td><td>CD-ROM</td><td>4.88</td><td>2.00</td><td>17</td><td></td></... | <table><tr><td></td><td></td></tr><tr><td>Items from CAD and renal failure (lecture format the same for each group)</td><td>Live lecture</td></tr><tr><td></td><td>CD-ROM</td></tr><tr><td></td><td>t-test†</td></tr><tr><td></td><td>Mann Whitney U</td></tr><tr><td></td><td>Levene's Test for equality of variances</td></tr>... | <table><tr><td>Mean</td><td>SD</td><td>No.</td><td>p-value</td></tr><tr><td>4.42</td><td>1.08</td><td>12</td><td></td></tr><tr><td>4.88</td><td>2.00</td><td>17</td><td></td></tr><tr><td></td><td></td><td></td><td>0.22 (one-tailed)</td></tr><tr><td></td><td></td><td></td><td>0.56 (exact test)</td></tr><tr><td></td><td><... |
2a3bace9805fc9ff3ca7d7b16fa151ee46e596d7f94c000c01c2a69d0f669459.png | simple | <table><tr><td>Drugs</td></tr><tr><td>Acetaminophen</td></tr><tr><td>Antiretroviral therapy (e.g., stavudine, zidovudine, and lamivudine)</td></tr><tr><td>β-2 agonists (e.g., salbutamol, terbutaline)</td></tr><tr><td>Biguanides (e.g., metformin, phenformin)</td></tr><tr><td>Isoniazid</td></tr><tr><td>Lactulose</td... | <table><tr><td>Drugs</td></tr><tr><td>Acetaminophen</td></tr><tr><td>Antiretroviral therapy (e.g., stavudine, zidovudine, and lamivudine)</td></tr><tr><td>β-2 agonists (e.g., salbutamol, terbutaline)</td></tr><tr><td>Biguanides (e.g., metformin, phenformin)</td></tr><tr><td>Isoniazid</td></tr></table> | <table><tr><td>Lactulose</td></tr><tr><td>Linezolid</td></tr><tr><td>Nalidixic acid</td></tr><tr><td>Niacin</td></tr><tr><td>Nitroprusside sodium</td></tr><tr><td>Propofol</td></tr><tr><td>Simvastatin</td></tr><tr><td>Theophylline</td></tr><tr><td>Vasoactive drugs (e.g., epinephrine, norepinephrine)</td></tr></table> |
1beda84732f8319bea512848c3704981a8380033bf2f589b3576356924d77596.png | complex | <table><tr><td rowspan="3">AVERAGE PROBABILITY</td><td colspan="4">Sensitivity</td><td colspan="4">Specificity</td><td colspan="4">AUC</td></tr><tr><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td ro... | <table><tr><td rowspan="3">AVERAGE PROBABILITY</td><td colspan="4">Sensitivity</td><td colspan="4">Specificity</td><td colspan="4">AUC</td></tr><tr><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td ro... | <table><tr><td rowspan="3">AVERAGE PROBABILITY</td><td colspan="4">Sensitivity</td><td colspan="4">Specificity</td><td colspan="4">AUC</td></tr><tr><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td ro... |
b6dfd35bc7baf4c99e36abd0fa992766575605fc7956efedea48185eed7fa673.png | complex | <table><tr><td></td><td></td><td colspan="3">Recommended or adequate treatment</td></tr><tr><td>Characteristic</td><td>No. of consultations or mean value</td><td>OR (95% CI)</td><td>n (%)</td><td>OR (95% CI)</td></tr><tr><td><i>Final multivariate models</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Health wo... | <table><tr><td></td></tr><tr><td>Characteristic</td></tr><tr><td>Final multivariate models</td></tr><tr><td>Health worker received</td></tr><tr><td>Study supports</td></tr><tr><td>Usual supports</td></tr><tr><td>No. supervisory visits, past 6 months (ranging from 0-4)</td></tr><tr><td>Consultation duration, in minutes ... | <table><tr><td></td><td colspan="3">Recommended or adequate treatment</td></tr><tr><td>No. of consultations or mean value</td><td>OR (95% CI)</td><td>n (%)</td><td>OR (95% CI)</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>N = 28</td><td>3.0 (1.0, 8.6)</td><td... |
1b3d128b8aaecb59ca4f2cdd92baa74300481a4418c43350e8dc76f9184b5aab.png | complex | <table><tr><td>Gender</td><td colspan="5">Genotype</td></tr><tr><td></td><td>A</td><td>B</td><td>C</td><td>D</td><td>Not typed</td></tr><tr><td>Male</td><td>30</td><td>9</td><td>48</td><td>45</td><td>6</td></tr><tr><td>Female</td><td>3</td><td>3</td><td>7</td><td>16</td><td>2</td></tr><tr><td>Total</td><td>33(19.53%)</... | <table><tr><td>Gender</td><td colspan="5">Genotype</td></tr><tr><td></td><td>A</td><td>B</td><td>C</td><td>D</td><td>Not typed</td></tr></table> | <table><tr><td>Male</td><td>30</td><td>9</td><td>48</td><td>45</td><td>6</td></tr><tr><td>Female</td><td>3</td><td>3</td><td>7</td><td>16</td><td>2</td></tr><tr><td>Total</td><td>33(19.53%)</td><td>12(7.10%)</td><td>55(32.54%)</td><td>61(36.09%)</td><td>8(4.73%)</td></tr></table> |
763a08cfa3c1f4cb83763688c470457ae4b649bedf378e3009a9d521a7341d32.png | simple | <table><tr><td>Semen variable</td><td>Before maca <i>N</i> = 9</td><td>After maca <i>N</i> = 9</td><td><i>P</i> value</td></tr><tr><td>Volume (mL)</td><td>2.23 ± 0.28</td><td>2.91 ± 0.28</td><td><0.05</td></tr><tr><td>pH</td><td>7.47 ± 0.09</td><td>7.44 ± 0.07</td><td>NS</td></tr><tr><td>Sperm co... | <table><tr><td>Semen variable</td><td>Before maca N = 9</td><td>After maca N = 9</td></tr><tr><td>Volume (mL)</td><td>2.23 ± 0.28</td><td>2.91 ± 0.28</td></tr><tr><td>pH</td><td>7.47 ± 0.09</td><td>7.44 ± 0.07</td></tr><tr><td>Sperm count (106/mL)</td><td>67.06 ± 18.61</td><td>90.33 ± 20.46</td></tr><tr><td>Total sperm... | <table><tr><td>P value</td></tr><tr><td><0.05</td></tr><tr><td>NS</td></tr><tr><td>NS</td></tr><tr><td><0.05</td></tr><tr><td><0.05</td></tr><tr><td>NS</td></tr><tr><td><0.05</td></tr><tr><td>NS</td></tr></table> |
063e362196cdf73d84551812d618728600851bd073ac07a3809294938b633f97.png | complex | <table><tr><td colspan="2">Ultraviolet (UV)-Curable Resin</td></tr><tr><td>Density</td><td>0.95 mm</td></tr><tr><td>Viscosity</td><td>600 MPa·s</td></tr></table> | <table><tr><td colspan="2">Ultraviolet (UV)-Curable Resin</td></tr></table> | <table><tr><td>Density</td><td>0.95 mm</td></tr><tr><td>Viscosity</td><td>600 MPa·s</td></tr></table> |
760039d820299577984ff596e3e2599e805357d6534e406c3a85c0eadbe78628.png | simple | <table><tr><td></td><td>CNB</td><td>Surgical biopsy</td></tr><tr><td>Procedures/patients</td><td>66/591</td><td>20/20</td></tr><tr><td>Males/females</td><td>32/27</td><td>15/5</td></tr><tr><td>Median age (range)</td><td>63.5 (24–85)</td><td>60 (42–72)</td></tr><tr><td>>75 years old</td><td>11</td><td>0</... | <table><tr><td></td><td>CNB</td><td>Surgical biopsy</td></tr><tr><td>Procedures/patients</td><td>66/591</td><td>20/20</td></tr></table> | <table><tr><td>Males/females</td><td>32/27</td><td>15/5</td></tr><tr><td>Median age (range)</td><td>63.5 (24–85)</td><td>60 (42–72)</td></tr><tr><td>>75 years old</td><td>11</td><td>0</td></tr><tr><td>Imaging modalities</td><td>CT 51 US 15</td><td>–</td></tr><tr><td>Surgical procedures</td><td>–</td><td>Laparotomy 15 L... |
fef2e742147776a91ba82a29eb79fe6b5d6843c3c32c3aa5cc4eb43a9e8379a6.png | simple | <table><tr><td>Microorganisms</td><td>ICU-A</td><td>ICU-B</td><td>ICU-C</td><td>Total</td></tr><tr><td>Gram-positive cocci</td><td>23</td><td>10</td><td>8</td><td>41</td></tr><tr><td>Coagulase-negative <i>Staphylocci</i></td><td>13</td><td>9</td><td>2</td><td>24</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>9</... | <table><tr><td>Microorganisms</td><td>ICU-A</td><td>ICU-B</td><td>ICU-C</td><td>Total</td></tr><tr><td>Gram-positive cocci</td><td>23</td><td>10</td><td>8</td><td>41</td></tr><tr><td>Coagulase-negative Staphylocci</td><td>13</td><td>9</td><td>2</td><td>24</td></tr><tr><td>Staphylococcus aureus</td><td>9</td><td>0</td><... | <table><tr><td>Other Gram-negative Bacilli</td><td>3</td><td>0</td><td>4</td><td>7</td></tr><tr><td>Yeasts</td><td>4</td><td>0</td><td>1</td><td>5</td></tr><tr><td>Total</td><td>42</td><td>11</td><td>18</td><td>71</td></tr></table> |
5f0d4864791b2f64b34cf968f64b27e4904bd8ce923c120143bba89c0a7b8fdf.png | simple | <table><tr><td>Dataset <sup>a</sup></td><td>KNG95</td><td>KNG01</td><td>FKO</td><td>NGY</td><td>KMM</td><td>NGN</td></tr><tr><td>Date (FY)</td><td>1995–1996</td><td>2001–2003</td><td>2003</td><td>2004</td><td>2011–2012</td><td>2013</td></tr><tr><td>Location <sup>b</sup></td><td>KNG Pref.</td><td>KNG P... | <table><tr><td>Dataset a</td><td>KNG95</td><td>KNG01</td><td>FKO</td><td>NGY</td><td>KMM</td><td>NGN</td></tr><tr><td>Date (FY)</td><td>1995–1996</td><td>2001–2003</td><td>2003</td><td>2004</td><td>2011–2012</td><td>2013</td></tr></table> | <table><tr><td>Location b</td><td>KNG Pref.</td><td>KNG Pref.</td><td>FKO Pref.</td><td>NGY City</td><td>KMM Pref.</td><td>NGN Pref.</td></tr><tr><td>Line c</td><td>TSL</td><td>TSL</td><td>SSL</td><td>TSL</td><td>KSL</td><td>HSL</td></tr><tr><td>Number of trains d</td><td></td><td></td><td></td><td></td><td></td><td></... |
f118e6f8afdb0040c7217d574199c122d1ff2f8ab9de6f300910bf62317c53f1.png | simple | <table><tr><td>Country</td><td>Author</td><td>Setting</td><td>Number</td><td>Measure</td><td>Prevalence</td></tr><tr><td>Lesotho</td><td>Hollifield <i>et al.</i> 1990</td><td>Rural</td><td>356</td><td>DIS</td><td>23.5% F14.7% M</td></tr><tr><td>Zimbabawe</td><td>Abas & Broadhead, 1997</td><td>Urban</td><td>172</td>... | <table><tr><td>Country</td><td>Author</td><td>Setting</td></tr><tr><td>Lesotho</td><td>Hollifield et al. 1990</td><td>Rural</td></tr><tr><td>Zimbabawe</td><td>Abas & Broadhead, 1997</td><td>Urban</td></tr><tr><td>South Africa</td><td>Haavenaar et al. 2008</td><td>Periurban</td></tr><tr><td>South Africa</td><td>Haavenaa... | <table><tr><td>Number</td><td>Measure</td><td>Prevalence</td></tr><tr><td>356</td><td>DIS</td><td>23.5% F14.7% M</td></tr><tr><td>172</td><td>SSQ</td><td>15.7% F 1 month, 30.8% F 1 year</td></tr><tr><td>209</td><td>SRQ</td><td>34.9% M and F</td></tr><tr><td>222</td><td>SRQ</td><td>27.0% M and F</td></tr><tr><td>257</td... |
69815701c7fbdd688b673bb8ad40c02d0602c2f4ed42deaf83cb162d72868b6f.png | complex | <table><tr><td><i>Test</i></td><td> </td><td><i>Positives (%)</i></td><td><i>Negatives (%)</i></td></tr><tr><td colspan="4"><i>T=3months</i></td></tr><tr><td>Culture (N=305)</td><td>Eradication</td><td>11 (7)</td><td>141 (93)</td></tr><tr><td> </td><td>Placebo</td><td>99 (65)</td><td>54 (35)</td></tr><tr><td>H&E st... | <table><tr><td>Test</td><td></td><td>Positives (%)</td><td>Negatives (%)</td></tr><tr><td colspan="4">T=3months</td></tr><tr><td>Culture (N=305)</td><td>Eradication</td><td>11 (7)</td><td>141 (93)</td></tr><tr><td></td><td>Placebo</td><td>99 (65)</td><td>54 (35)</td></tr><tr><td>H&E stains (N=305)</td><td>Eradication</... | <table><tr><td></td><td>Placebo</td><td>7 (20)</td><td>27 (79)</td></tr><tr><td>Serology (N=203)</td><td>Eradication</td><td>92 (91)</td><td>9 (9)</td></tr><tr><td></td><td>Placebo</td><td>94 (92)</td><td>8 (8)</td></tr><tr><td colspan="4">T=12months</td></tr><tr><td>Serology (N=304)</td><td>Eradication</td><td>96 (64)... |
63d3ef0367ea0b9793c1f38edef91fe09cc6e008d32716ff00ac22339b83f2a3.png | complex | <table><tr><td>Characteristic</td><td>Normal No %</td><td>Underweight No %</td><td>Overweight No %</td><td>Obese No %</td><td>Total</td></tr><tr><td colspan="6">Social class</td></tr><tr><td>Upper</td><td>244 (84.4)</td><td>12 (4.1)</td><td>25 (8.7)</td><td>8 (2.8)</td><td>289 (100)</td></tr><tr><td>Middle</td><td>327 ... | <table><tr><td>Characteristic</td><td>Normal No %</td></tr><tr><td colspan="2">Social class</td></tr><tr><td>Upper</td><td>244 (84.4)</td></tr><tr><td>Middle</td><td>327 (86.7)</td></tr><tr><td>Lower</td><td>248 (84.4)</td></tr><tr><td colspan="2">Mother’s education</td></tr><tr><td>No education</td><td>47 (90.4)</td><... | <table><tr><td>Underweight No %</td><td>Overweight No %</td><td>Obese No %</td><td>Total</td></tr><tr><td colspan="4">Social class</td></tr><tr><td>12 (4.1)</td><td>25 (8.7)</td><td>8 (2.8)</td><td>289 (100)</td></tr><tr><td>23 (6.1)</td><td>20 (5.3)</td><td>7 (1.9)</td><td>377 (100)</td></tr><tr><td>26 (8.8)</td><td>1... |
874a03976ceb932a0666a02c3e1818d8ffe17dda7d27304dd81e4cd7da94d98c.png | simple | <table><tr><td>Hyperparameter</td><td>Value</td><td>Number of Occurrences</td></tr><tr><td>criterion</td><td>entropy</td><td>7</td></tr><tr><td></td><td>gini</td><td>37</td></tr><tr><td>max_features</td><td>0.1</td><td>4</td></tr><tr><td></td><td>0.25</td><td>5</td></tr><tr><td></td><td>0.5</td><td>7</td></tr><tr><td><... | <table><tr><td>Hyperparameter</td><td>Value</td><td>Number of Occurrences</td></tr><tr><td>criterion</td><td>entropy</td><td>7</td></tr><tr><td></td><td>gini</td><td>37</td></tr><tr><td>max_features</td><td>0.1</td><td>4</td></tr><tr><td></td><td>0.25</td><td>5</td></tr><tr><td></td><td>0.5</td><td>7</td></tr><tr><td><... | <table><tr><td>100</td><td>17</td></tr><tr><td>50</td><td>16</td></tr><tr><td>500</td><td>6</td></tr></table> |
65c6b7736ff0e97a8f462f069466c4ed95b51613737d7b23104ef3a128f857fb.png | simple | <table><tr><td>ID</td><td>Position*</td><td>Tm
(°C)</td><td>Sequence (5′→3′)</td><td>Size (bp)</td></tr><tr><td>MYOC1</td><td>353–509</td><td>62</td><td>F: GGCTGGCTCCCC AGTATATA</td><td>174</td></tr><tr><td></td><td></td><td></td><td>R: ACAGCTGGCATCTCAGGC</td><td></td></tr><tr><td>MYO... | <table><tr><td>ID</td><td>Position*</td><td>Tm
(°C)</td><td>Sequence (5′→3′)</td><td>Size (bp)</td></tr><tr><td>MYOC1</td><td>353–509</td><td>62</td><td>F: GGCTGGCTCCCC AGTATATA</td><td>174</td></tr><tr><td></td><td></td><td></td><td>R: ACAGCTGGCATCTCAGGC</td><td></td></tr><tr><td>MYOC2</td><td>491–658</td><td>62</td><... | <table><tr><td>ID</td><td>Position*</td><td>Tm
(°C)</td><td>Sequence (5′→3′)</td><td>Size (bp)</td></tr><tr><td></td><td></td><td></td><td>R: CCTGGCCAGATTCTCATTTT</td><td></td></tr><tr><td>MYOC6</td><td>928–1095</td><td>63</td><td>F: TGGAGGAAGAGAAGAAGCGA</td><td>187</td></tr><tr><td></td><td></td><td></td><td>R: CTGCTG... |
f2ef6841e14161087a866cbc513725da56f73ac452ca9d04da08fa62cf83d79d.png | simple | <table><tr><td>Study</td><td>Status</td><td>Results</td><td>NCT identifier</td></tr><tr><td>Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer</td><td>Recruiting</td><td>Pending</td><td>NCT00889343</td></tr><tr><td>Sorafenib + capecitabine in patients with pretreated advanced... | <table><tr><td>Study</td><td>Status</td><td>Results</td></tr><tr><td>Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer</td><td>Recruiting</td><td>Pending</td></tr><tr><td>Sorafenib + capecitabine in patients with pretreated advanced CRC</td><td>Recruiting</td><td>Pending</td... | <table><tr><td>NCT identifier</td></tr><tr><td>NCT00889343</td></tr><tr><td>NCT01290926</td></tr><tr><td>NCT00326495</td></tr><tr><td>NCT00839111</td></tr><tr><td>NCT01471353</td></tr><tr><td>NCT00989469</td></tr><tr><td>NCT00134069</td></tr><tr><td>NCT00826540</td></tr><tr><td>NCT00869570</td></tr></table> |
b400d0352a248fa88eea52d041ca65cd9a5638698f557b2fccb92abd941aab9c.png | complex | <table><tr><td>Organism</td><td>Gene targeted</td><td>Primer Sequences 5' - > 3'</td><td>Amplicon size (bp)</td><td>Reference</td></tr><tr><td rowspan="6"><i>A. phagocytophilum</i></td><td rowspan="2"><i>ankA</i></td><td>F: CTATCATCCTTGGGTAGTGGCCT</td><td rowspan="2">223</td><td rowspan="6">This study</td></tr><tr><... | <table><tr><td>Organism</td><td>Gene targeted</td><td>Primer Sequences 5' - > 3'</td><td>Amplicon size (bp)</td></tr><tr><td rowspan="6">A. phagocytophilum</td><td rowspan="2">ankA</td><td>F: CTATCATCCTTGGGTAGTGGCCT</td><td rowspan="2">223</td></tr><tr><td>R: CTTCTGGTGTTCTCGGACCTTC</td></tr><tr><td rowspan="2">gltA</td... | <table><tr><td>Reference</td></tr><tr><td rowspan="6">This study</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="5">[30]</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td></td></tr></table> |
b244abcf5c5a119a91e07baa98e1036300dd92eb7a79ddbe8f58ab36dea3cc21.png | simple | <table><tr><td>Day</td><td>Interval</td><td>Vial</td><td>Dose (mL)</td><td>Allergen dose (mcg/mL)</td></tr><tr><td>1</td><td></td><td>2</td><td>0.1 + 0.2</td><td>0.0025 + 0.005</td></tr><tr><td>8</td><td>Weekly</td><td>2</td><td>0.4 + 0.4</td><td>0.01 + 0.01</td></tr><tr><td>15</td><td>Weekly</td><td>3</td><td>0.1 + 0.... | <table><tr><td>Day</td><td>Interval</td><td>Vial</td><td>Dose (mL)</td><td>Allergen dose (mcg/mL)</td></tr><tr><td>1</td><td></td><td>2</td><td>0.1 + 0.2</td><td>0.0025 + 0.005</td></tr><tr><td>8</td><td>Weekly</td><td>2</td><td>0.4 + 0.4</td><td>0.01 + 0.01</td></tr><tr><td>15</td><td>Weekly</td><td>3</td><td>0.1 + 0.... | <table><tr><td>Day</td><td>Interval</td><td>Vial</td><td>Dose (mL)</td><td>Allergen dose (mcg/mL)</td></tr><tr><td>22</td><td>Weekly</td><td>3</td><td>0.4 + 0.4</td><td>0.1 + 0.1</td></tr><tr><td>37</td><td>Fortnightly</td><td>3</td><td>0.8</td><td>0.2</td></tr><tr><td>67</td><td>Monthly</td><td>3</td><td>0.8</td><td>0... |
5a6edc3068e8f3a5fb83a6678536e5507d5fc9610dd1ee8926e523327fa31b62.png | simple | <table><tr><td> </td><td>Control (N = 20)</td><td>Half dose (N = 20)</td><td>Early administration (N = 21)</td></tr><tr><td>Endometrial thickness</td><td> </td><td> </td><td> </td></tr><tr><td>Mean ± SD (mm)</td><td>6.7 ± 1.8</td><td>8.6 ± 1.5<sup>a</sup></td><td>9.4 ± 1.5<sup>a</sup></td></tr><tr><... | <table><tr><td></td><td>Control (N = 20)</td><td>Half dose (N = 20)</td><td>Early administration (N = 21)</td></tr><tr><td>Endometrial thickness</td><td></td><td></td><td></td></tr><tr><td>Mean ± SD (mm)</td><td>6.7 ± 1.8</td><td>8.6 ± 1.5a</td><td>9.4 ± 1.5a</td></tr><tr><td>< 8 mm</td><td>17 (85.0%)</td><td>6(30.0%)<... | <table><tr><td></td><td>Control (N = 20)</td><td>Half dose (N = 20)</td><td>Early administration (N = 21)</td></tr><tr><td>≥ 8 mm</td><td>3(15.0%)</td><td>14(70.0%)a</td><td>19(90.4%)a</td></tr><tr><td>Days until follicles maturation</td><td>12.0 ± 1.5</td><td>13.6 ± 2.7b</td><td>11.6 ± 2.3</td></tr><tr><td>Number of f... |
8733316b52e6ab7e632307b4a49f1f081c6e2c21f4867c7c5c16ecdeba9b79f7.png | simple | <table><tr><td>Study report</td><td>Location</td><td>Source of cases</td><td>Number of cases</td><td>Source of comparison group without diarrhoea</td><td>Matching of comparison group</td><td>Number of children without diarrhoea</td></tr><tr><td>Bangladesh 1992a [16]</td><td>Matlab (rural)</td><td>Active household surve... | <table><tr><td>Study report</td><td>Location</td><td>Source of cases</td><td>Number of cases</td><td>Source of comparison group without diarrhoea</td><td>Matching of comparison group</td></tr><tr><td>Bangladesh 1992a [16]</td><td>Matlab (rural)</td><td>Active household surveillance</td><td>Varied by pathogen (68 – 184)... | <table><tr><td>Number of children without diarrhoea</td></tr><tr><td>Varied by pathogen (67 – 164)</td></tr><tr><td>Varied by pathogen (46 – 213)</td></tr><tr><td>92</td></tr><tr><td>32</td></tr><tr><td>115</td></tr><tr><td>38</td></tr><tr><td>42</td></tr><tr><td>443</td></tr></table> |
e2e83568d73e008e5806a3f65c8d9fd503f190065e941245fd096305c34a8091.png | complex | <table><tr><td>Dependent variable</td><td colspan="3">Acute MI</td><td colspan="3">Genotype</td><td colspan="3">Acute MI × Genotype</td></tr><tr><td> </td><td>F</td><td><i>p</i></td><td>Partial Eta squared</td><td>F</td><td><i>p</i></td><td>Partial Eta squared</td><td>F</td><td><i>p</i></td><td>Partial Eta squared... | <table><tr><td>Dependent variable</td><td colspan="3">Acute MI</td><td colspan="3">Genotype</td><td colspan="3">Acute MI × Genotype</td></tr><tr><td></td><td>F</td><td>p</td><td>Partial Eta squared</td><td>F</td><td>p</td><td>Partial Eta squared</td><td>F</td><td>p</td><td>Partial Eta squared</td></tr></table> | <table><tr><td>Serum ACE2 Levels</td><td>19.22</td><td>0.00</td><td>0.29</td><td>1.69</td><td>0.19</td><td>0.04</td><td>11.98</td><td>0.00</td><td>0.16</td></tr></table> |
254e20697b355b07c146132a37eba4b00ccb0ada16f0ad605bbb3441cd4ed86f.png | simple | <table><tr><td></td><td>Early remission n = 387</td><td>Arm 1 n = 83</td><td>Arm 2 n = 78</td><td>OOP n = 50</td></tr><tr><td>Patients with AE*, n (%)</td><td>205/387 (53 %)</td><td>53/83 (64 %)</td><td>52/78 (67 %)</td><td>27/50 (54 %)</td></tr><tr><td>Total number of AE</td><td>408</td><td>129</td><td>109</td><td>58<... | <table><tr><td></td><td>Early remission n = 387</td><td>Arm 1 n = 83</td><td>Arm 2 n = 78</td><td>OOP n = 50</td></tr><tr><td>Patients with AE*, n (%)</td><td>205/387 (53 %)</td><td>53/83 (64 %)</td><td>52/78 (67 %)</td><td>27/50 (54 %)</td></tr><tr><td>Total number of AE</td><td>408</td><td>129</td><td>109</td><td>58<... | <table><tr><td>Hair loss/thinning</td><td>4</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Sicca complaints</td><td>3</td><td>–</td><td>–</td><td>1</td></tr><tr><td>Eczema</td><td>3</td><td>1</td><td>–</td><td>–</td></tr><tr><td>Other</td><td>16</td><td>8</td><td>9</td><td>1</td></tr><tr><td>Infections</td><td>106</td>... |
e2db6de6e6e36f1a0c76147c073e8c5a36911944670b9e3e15c875ee15363d0d.png | simple | <table><tr><td>Test</td><td>Meaning</td><td>P-value</td></tr><tr><td>1 vs. only fixed effects</td><td>QTL additive effect</td><td>6 × 10<sup>-7</sup></td></tr><tr><td>2 vs. 0</td><td>QTL additive effect conditional on infinitesimal effect</td><td>3 × 10<sup>-7</sup></td></tr><tr><td>3 vs. 0</td><td>QTL additi... | <table><tr><td>Test</td><td>Meaning</td><td>P-value</td></tr></table> | <table><tr><td>1 vs. only fixed effects</td><td>QTL additive effect</td><td>6 × 10-7</td></tr><tr><td>2 vs. 0</td><td>QTL additive effect conditional on infinitesimal effect</td><td>3 × 10-7</td></tr><tr><td>3 vs. 0</td><td>QTL additive and dominance effects conditional on infinitesimal effect</td><td>2 × 10-6</td></tr... |
f7285b4ee8e1a1abf1744d02b65a3e8b5c43df4535f789887730654f19436489.png | simple | <table><tr><td>Direct costs of NSIs</td><td> </td></tr><tr><td>Testing for blood-borne viruses [6,26-30] in:</td><td> </td></tr><tr><td><i>NSI recipient – initial test</i></td><td>€38.76</td></tr><tr><td><i>NSI recipient – follow-up test</i></td><td>€58.52</td></tr><tr><td><i>Source patient (if ... | <table><tr><td>Direct costs of NSIs</td></tr><tr><td>Testing for blood-borne viruses [6,26-30] in:</td></tr><tr><td>NSI recipient – initial test</td></tr><tr><td>NSI recipient – follow-up test</td></tr><tr><td>Source patient (if known)</td></tr><tr><td>Cost of staffing and administration per NSI [26,31]</td></tr><tr><t... | <table><tr><td></td></tr><tr><td></td></tr><tr><td>€38.76</td></tr><tr><td>€58.52</td></tr><tr><td>€43.91</td></tr><tr><td>€68.81</td></tr><tr><td></td></tr><tr><td>€374.61</td></tr><tr><td>€918.76</td></tr><tr><td>€2,377.44</td></tr><tr><td></td></tr><tr><td>€16,127.76</td></tr><tr><td>€16,999.83</td></tr></table> |
6494492462df9bf683a093496110ef45757a236caecf24c9fcbc47370bd5c86b.png | simple | <table><tr><td>Number of free nicotine patches provided</td><td>Group 12-week supply</td><td>Group 24-week supply</td><td>Group 36-week supply contingent upon first 2-weeks of use</td><td>Group 46-week supply</td><td>Group 58-week supply</td></tr><tr><td>12-month quit rate*</td><td>31.0%</td><td>21.0%</td><td>15.5%</td... | <table><tr><td>Number of free nicotine patches provided</td><td>Group 12-week supply</td><td>Group 24-week supply</td><td>Group 36-week supply contingent upon first 2-weeks of use</td><td>Group 46-week supply</td><td>Group 58-week supply</td></tr><tr><td>12-month quit rate*</td><td>31.0%</td><td>21.0%</td><td>15.5%</td... | <table><tr><td>Number of free nicotine patches provided</td><td>Group 12-week supply</td><td>Group 24-week supply</td><td>Group 36-week supply contingent upon first 2-weeks of use</td><td>Group 46-week supply</td><td>Group 58-week supply</td></tr><tr><td>Relapsed smokers*</td><td>18.9%</td><td>14.9%</td><td>16.4%</td><... |
899b04292498a3700beddc49f7c6f4cadffa33f2619d4e86131fceb216b0bb7f.png | simple | <table><tr><td></td><td>mNCV</td><td>CMAP</td></tr><tr><td>Patient 1</td><td>39 m/s</td><td>3.4 mV</td></tr><tr><td>Patient 2</td><td>45 m/s</td><td>4.0 mV</td></tr><tr><td>Patient 3</td><td>32 m/s</td><td>1.5 mV</td></tr><tr><td>Patient 4</td><td>32.4 m/s</td><td>5.1 mV</td></tr><tr><td>Patient 5</td><td>34.1 m/s</td>... | <table><tr><td></td></tr><tr><td>Patient 1</td></tr><tr><td>Patient 2</td></tr><tr><td>Patient 3</td></tr><tr><td>Patient 4</td></tr><tr><td>Patient 5</td></tr></table> | <table><tr><td>mNCV</td><td>CMAP</td></tr><tr><td>39 m/s</td><td>3.4 mV</td></tr><tr><td>45 m/s</td><td>4.0 mV</td></tr><tr><td>32 m/s</td><td>1.5 mV</td></tr><tr><td>32.4 m/s</td><td>5.1 mV</td></tr><tr><td>34.1 m/s</td><td>1.4 mV</td></tr></table> |
0dccac36c2ebe48d8286b35bcb2ee9941a8ee6be993cd61fee8a411a0f149f36.png | complex | <table><tr><td>Outcomes</td><td><i>N</i></td><td><i>p</i>-Value</td><td>B-Coefficient</td><td>95% Confidence Interval</td></tr><tr><td colspan="5">FSH</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>170</td><td><0.001</td><td>1.034</td><td>(0.554; 1.514)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>110</t... | <table><tr><td>Outcomes</td><td>N</td><td>p-Value</td><td>B-Coefficient</td></tr><tr><td colspan="4">FSH</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>170</td><td><0.001</td><td>1.034</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>110</td><td><0.001</td><td>1.416</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</... | <table><tr><td>95% Confidence Interval</td></tr><tr><td>FSH</td></tr><tr><td>(0.554; 1.514)</td></tr><tr><td>(0.765; 2.067)</td></tr><tr><td>(0.986; 2.657)</td></tr><tr><td>(−1.985; 0.590)</td></tr><tr><td>LH</td></tr><tr><td>(0.309; 0.781)</td></tr><tr><td>(0.843; 1.484)</td></tr><tr><td>(0.545; 1.380)</td></tr><tr><t... |
291eb806b20c1095b9b1c63dc0677932199d2ca1bc459dfc6fa813d3f333c265.png | complex | <table><tr><td></td><td colspan="2">OS</td><td colspan="2">PFS</td><td colspan="2">LR</td></tr><tr><td><i>Parameter</i></td><td>HR [95% CI]</td><td><i>p</i>-value</td><td>HR [95% CI]</td><td><i>p</i>-value</td><td>HR [95% CI]</td><td><i>p</i>-value</td></tr><tr><td>RT mode (IMRT vs. 3DCRT)</td><td>0.716 [0.430; 1.191]<... | <table><tr><td></td><td colspan="2">OS</td></tr><tr><td>Parameter</td><td>HR [95% CI]</td><td>p-value</td></tr><tr><td>RT mode (IMRT vs. 3DCRT)</td><td>0.716 [0.430; 1.191]</td><td>0.198</td></tr><tr><td>Age (continuous)</td><td>1.006 [0.978; 1.035]</td><td>0.676</td></tr><tr><td>KPS (continuous)</td><td>1.004 [0.973; ... | <table><tr><td colspan="2">PFS</td><td colspan="2">LR</td></tr><tr><td>HR [95% CI]</td><td>p-value</td><td>HR [95% CI]</td><td>p-value</td></tr><tr><td>0.830 [0.512; 1.344]</td><td>0.448</td><td>0.812 [0.356; 1.852]</td><td>0.620</td></tr><tr><td>1.009 [0.981; 1.037]</td><td>0.525</td><td>0.962 [0.906; 1.022]</td><td>0... |
421bd46481a17f3b10f64a5d4b58974e0d9ee9d555b88b914e3765259df78013.png | complex | <table><tr><td>Proliferation status (E2F1)</td><td colspan="3">NKI 70-gene signature prognosis</td></tr><tr><td></td><td>Good</td><td>Poor</td><td>Total</td></tr><tr><td>E2F1 ≤ p30</td><td>4/69 (5.7%)</td><td>6/21 (28.6%)</td><td>10/90 (11.1%)</td></tr><tr><td>E2F1 > p30</td><td>12/46 (26.1%)</td><td>79/159 (4... | <table><tr><td>Proliferation status (E2F1)</td><td colspan="3">NKI 70-gene signature prognosis</td></tr><tr><td></td><td>Good</td><td>Poor</td><td>Total</td></tr><tr><td>E2F1 ≤ p30</td><td>4/69 (5.7%)</td><td>6/21 (28.6%)</td><td>10/90 (11.1%)</td></tr></table> | <table><tr><td>Proliferation status (E2F1)</td><td colspan="3">NKI 70-gene signature prognosis</td></tr><tr><td></td><td>Good</td><td>Poor</td><td>Total</td></tr><tr><td>E2F1 > p30</td><td>12/46 (26.1%)</td><td>79/159 (49.6%)</td><td>91/205 (44.4%)</td></tr><tr><td>Total</td><td>16/115 (13.9%)</td><td>85/180 (47.2%)</t... |
20e6ec3568a660c9bb15b2777d4c3fcf50a21ceffeb3fbb91f44225801289d02.png | complex | <table><tr><td>Length</td><td>Coefficient</td><td>Std. Err.</td><td>z</td><td><i>P</i> > z</td><td>[95% Conf.</td><td>Interval]</td></tr><tr><td>Days</td><td>−0.1 mm</td><td>0.1 mm</td><td>−1.16</td><td>0.25</td><td>−.4 mm</td><td>.1 mm</td></tr><tr><td>Female vs. Male</td><td>18 mm</td><td>3 mm</t... | <table><tr><td>Length</td><td>Coefficient</td><td>Std. Err.</td><td>z</td><td>P > z</td><td>[95% Conf.</td><td>Interval]</td></tr><tr><td>Days</td><td>−0.1 mm</td><td>0.1 mm</td><td>−1.16</td><td>0.25</td><td>−.4 mm</td><td>.1 mm</td></tr><tr><td>Female vs. Male</td><td>18 mm</td><td>3 mm</td><td>5.59</td><td>0.000</td... | <table><tr><td>Length constant</td><td>137 mm</td><td>5 mm</td><td>28.14</td><td>0.000</td><td>127 mm</td><td>147 mm</td></tr></table> |
efde415738d906ee462aa0b1733cbf6dd30861c6a66d95f09a72534f113f49b3.png | complex | <table><tr><td></td><td colspan="4">PM (mg/m<sup>3</sup>)</td><td colspan="4">Endotoxin (EU/m<sup>3</sup>)</td></tr><tr><td>Fuel/particle size</td><td><i>n</i></td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>< LOD (<i>n</i>)</td></tr><tr><td colspan="9"... | <table><tr><td></td><td colspan="4">PM (mg/m3)</td><td colspan="4">Endotoxin (EU/m3)</td></tr><tr><td>Fuel/particle size</td><td>n</td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>< LOD (n)</td></tr></table> | <table><tr><td colspan="9">Nepal, TIP</td></tr><tr><td>Wood</td><td>16</td><td>0.22–4.08</td><td>1.14 (1.12)</td><td>0.68</td><td>6–371</td><td>100 (113)</td><td>43</td><td>4a</td></tr><tr><td>Dung</td><td>15</td><td>0.91–12.8</td><td>3.78 (3.51)</td><td>2.33</td><td>133–1,002</td><td>498 (291)</td><td>365</td><td>0</t... |
22e7c425bfb1ebec76973dd533703938947a547615afa0a0e764277f48745f66.png | complex | <table><tr><td></td><td colspan="3">Model 2</td></tr><tr><td></td><td>Coefficient</td><td>SE</td><td><i>P</i> > |<i>z</i>|</td></tr><tr><td>Salary</td><td>0.00006</td><td>9.79e − 06</td><td>0.000</td></tr><tr><td>Salary*health professionals</td><td>0.00001</td><td>0.00001</td><td>0.217</td></tr><tr><td>Place o... | <table><tr><td></td><td colspan="3">Model 2</td></tr><tr><td></td><td>Coefficient</td><td>SE</td><td>P > |z|</td></tr><tr><td>Salary</td><td>0.00006</td><td>9.79e − 06</td><td>0.000</td></tr><tr><td>Salary*health professionals</td><td>0.00001</td><td>0.00001</td><td>0.217</td></tr><tr><td>Place of work: district capita... | <table><tr><td></td><td colspan="3">Model 2</td></tr><tr><td></td><td>Coefficient</td><td>SE</td><td>P > |z|</td></tr><tr><td>opment*health professionals</td><td>89</td><td>6</td><td>.734</td></tr><tr><td>Availability of equipment and medicine</td><td>0.25184</td><td>0.05697</td><td>0.000</td></tr><tr><td>Availability ... |
43b784975af49add655c3eb4d733a7e0b1d230fa659a5627d07426d3833e6a49.png | complex | <table><tr><td colspan="2">Group</td><td>Operation</td><td>Treatment</td><td colspan="2">Dose</td><td>Frequency</td><td><i>n</i></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>(μg·kg<sup>−1</sup>)</td><td>(μg·kg<sup>−1</sup> per week)</td><td> </td><td> </td></tr><tr><td>1</td>... | <table><tr><td colspan="2">Group</td><td>Operation</td><td>Treatment</td><td colspan="2">Dose</td><td>Frequency</td><td>n</td></tr><tr><td></td><td></td><td></td><td></td><td>(μg·kg−1)</td><td>(μg·kg−1 per week)</td><td></td><td></td></tr><tr><td>1</td><td>Sham</td><td>Sham</td><td>Vehicle</td><td>—</td><td>—</td><td>3... | <table><tr><td></td><td></td><td></td><td>TPTD</td><td></td><td></td><td></td><td></td></tr><tr><td>13</td><td>D3V</td><td>OVX</td><td>Vehicle</td><td>—</td><td>—</td><td>3/day</td><td>5</td></tr><tr><td>14</td><td>D3L</td><td>OVX</td><td>TPTD</td><td>1.2</td><td>25.2</td><td>3/day</td><td>5</td></tr><tr><td>15</td><td... |
772df1547cbf0d6e0005e0b6d11a4399c3feffe037185ca9427498049ddaceb9.png | complex | <table><tr><td>Patient details</td><td>Preoperative data</td><td>Data prior to withdrawal of epidural catheter</td></tr><tr><td>Age</td><td>Time of epidural catheterization</td><td>Time of withdrawal of epidural catheter</td></tr><tr><td>Sex</td><td>Time of blood testing</td><td>Time of blood testing</td></tr><tr><td>E... | <table><tr><td>Patient details</td><td>Preoperative data</td><td>Data prior to withdrawal of epidural catheter</td></tr><tr><td>Age</td><td>Time of epidural catheterization</td><td>Time of withdrawal of epidural catheter</td></tr><tr><td></td><td>Time of bl</td><td>Time of bl</td></tr></table> | <table><tr><td>Patient details</td><td>Preoperative data</td><td>Data prior to withdrawal of epidural catheter</td></tr><tr><td>Sex</td><td>ood testing</td><td>ood testing</td></tr><tr><td>Epidural or intravenous analgesia</td><td>Activated partial thromboplastin time (aPTT)</td><td>Time and dosage of the last dose of ... |
ba3514353dd48cbe557ed3a8ddad3549ec5124796f4baefe81a57213634fd334.png | simple | <table><tr><td>Genotype</td><td>Frequency</td><td>Percentage</td></tr><tr><td>1 (all subtypes)</td><td>1999</td><td>7.038</td></tr><tr><td> 1(Undefined subtypes)</td><td>237</td><td>0.834</td></tr><tr><td> 1a</td><td>1369</td><td>4.82</td></tr><tr><td> 1b</td><td>336</td><td>1.183</td></tr><tr><td> 1c</td><td>57</td><t... | <table><tr><td>Genotype</td><td>Frequency</td><td>Percentage</td></tr><tr><td>1 (all subtypes)</td><td>1999</td><td>7.038</td></tr><tr><td>1(Undefined subtypes)</td><td>237</td><td>0.834</td></tr><tr><td>1a</td><td>1369</td><td>4.82</td></tr><tr><td>1b</td><td>336</td><td>1.183</td></tr><tr><td>1c</td><td>57</td><td>0.... | <table><tr><td>5 (all subtypes)</td><td>29</td><td>0.101</td></tr><tr><td>5 (Undefined subtypes)</td><td>5</td><td>0.017</td></tr><tr><td>5a</td><td>24</td><td>0.084</td></tr><tr><td>6(all subtypes)</td><td>37</td><td>0.13</td></tr><tr><td>6 (Undefined subtypes)</td><td>25</td><td>0.088</td></tr><tr><td>6</td><td>12</t... |
b3badbdc7d6abcc2fcc3e84f55e2e73c97ee66c540900826a08f09cc05427e02.png | simple | <table><tr><td>Target population</td><td>Approach</td><td>Number conducted</td><td>Target population reached</td></tr><tr><td>Male and female adolescents</td><td>FGD</td><td>6</td><td>48</td></tr><tr><td>Women with children under 5 years</td><td>FGD</td><td>6</td><td>32</td></tr><tr><td>Men whose children have or have ... | <table><tr><td>Target population</td><td>Approach</td><td>Number conducted</td><td>Target population reached</td></tr><tr><td>Male and female adolescents</td><td>FGD</td><td>6</td><td>48</td></tr><tr><td>Women with children under 5 years</td><td>FGD</td><td>6</td><td>32</td></tr><tr><td>Men whose children have or have ... | <table><tr><td>Target population</td><td>Approach</td><td>Number conducted</td><td>Target population reached</td></tr><tr><td>Traditional healer</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Director of Agriculture</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Unit committee members.</td><td>IDI</td><td>1</td><td... |
a625976138a844af473c995e122abe41bdc22b4df2d323ed92a5118748916022.png | simple | <table><tr><td>Landmarks</td><td>Lee et al. [13] Mean (mm) ± SD</td><td>Lee [16] Mean (mm) ± SD</td></tr><tr><td>Height of maxillary sinus roof</td><td>33.45 ± 2.83</td><td>33.83 ± 3.40</td></tr><tr><td>Maxillary sinus roof to posterior ethmoid roof</td><td>14.08 ± 3.03</td><td>Not measured</td... | <table><tr><td>Landmarks</td><td>Lee et al. [13] Mean (mm) ± SD</td><td>Lee [16] Mean (mm) ± SD</td></tr><tr><td>Height of maxillary sinus roof</td><td>33.45 ± 2.83</td><td>33.83 ± 3.40</td></tr><tr><td>Maxillary sinus roof to posterior ethmoid roof</td><td>14.08 ± 3.03</td><td>Not measured</td></tr><tr><td>Maxillary s... | <table><tr><td>Maxillary sinus roof to sphenoid floor</td><td>5.94 ± 2.94</td><td>6.18 ± 2.88</td></tr></table> |
818ca96ef6425e108693295fe7aed54999b0b5902466d0c697880ba97f2a391b.png | complex | <table><tr><td></td><td>Automatic selection 450 K</td><td>Automatic selection EPIC</td><td>IDOL EPIC</td><td><i>P</i><sup>a</sup></td></tr><tr><td>Probes</td><td>(<i>n</i> = 600)</td><td>(<i>n</i> = 600)</td><td>(<i>n</i> = 450)</td><td></td></tr><tr><td></td><td>N(%)</td><td>N(%)</td><td>N(%)</td><td></td></tr><tr><td... | <table><tr><td></td><td>Automatic selection 450 K</td><td>Automatic selection EPIC</td><td>IDOL EPIC</td><td>Pa</td></tr><tr><td>Probes</td><td>(n = 600)</td><td>(n = 600)</td><td>(n = 450)</td><td></td></tr><tr><td></td><td>N(%)</td><td>N(%)</td><td>N(%)</td><td></td></tr><tr><td>CpG present on 450 K array</td><td>600... | <table><tr><td></td><td>Automatic selection 450 K</td><td>Automatic selection EPIC</td><td>IDOL EPIC</td><td>Pa</td></tr><tr><td>Probes</td><td>(n = 600)</td><td>(n = 600)</td><td>(n = 450)</td><td></td></tr><tr><td></td><td>N(%)</td><td>N(%)</td><td>N(%)</td><td></td></tr><tr><td>CpG island</td><td>47 (8)</td><td>24 (... |
b9ae90f0c226646e3c3fa90b2627b6d24227d5c714cf6b2ea14517ee5553c30b.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td><i>P</i></td></tr><tr><td>Prior history of radiation</td><td>−1.350</td><td>.012</td></tr><tr><td>Volume per injection, mL</td><td>2.060</td><td>.094</td></tr></table> | <table><tr><td>Variable</td><td>Coefficient</td><td>P</td></tr><tr><td>Prior history of radiation</td><td>−1.350</td><td>.012</td></tr></table> | <table><tr><td>Volume per injection, mL</td><td>2.060</td><td>.094</td></tr></table> |
135caaff6edcfb710f0b21d24821f1399076302f648968dbbfd992aad1bb0d00.png | simple | <table><tr><td>Dosimetry Parameter</td><td>Planned</td><td>St Dev</td><td>Implanted</td><td>St Dev</td></tr><tr><td>D90 (Gy)</td><td>175.5</td><td>9.6</td><td>177.7</td><td>10.5</td></tr><tr><td>V100 (%)</td><td>97.9</td><td>1.6</td><td>97.9</td><td>1.5</td></tr><tr><td>V150 (%)</td><td>64.1</td><td>7.3</td><td>66.5</t... | <table><tr><td>Dosimetry Parameter</td><td>Planned</td><td>St Dev</td><td>Implanted</td><td>St Dev</td></tr></table> | <table><tr><td>D90 (Gy)</td><td>175.5</td><td>9.6</td><td>177.7</td><td>10.5</td></tr><tr><td>V100 (%)</td><td>97.9</td><td>1.6</td><td>97.9</td><td>1.5</td></tr><tr><td>V150 (%)</td><td>64.1</td><td>7.3</td><td>66.5</td><td>7.9</td></tr><tr><td>V200 (%)</td><td>21.6</td><td>5.9</td><td>26.1</td><td>7.3</td></tr></tabl... |
518f480df1fa433463a03a11f05984611f8267bdc1202d83e50e1e1e2cec94be.png | simple | <table><tr><td>Drug</td><td>Disease</td><td>NCT number</td><td>Phase</td></tr><tr><td>5-Azacitidine</td><td>Beta thalassemia</td><td>NCT00005934</td><td>Phase 2</td></tr><tr><td>5-Azacytidine + Na phenylbutyrate</td><td>Thalassemia major</td><td>NCT00007072</td><td>Phase 2</td></tr><tr><td>Resveratrol</td><td>Cardiovas... | <table><tr><td>Drug</td><td>Disease</td><td>NCT number</td><td>Phase</td></tr><tr><td>5-Azacitidine</td><td>Beta thalassemia</td><td>NCT00005934</td><td>Phase 2</td></tr><tr><td>5-Azacytidine + Na phenylbutyrate</td><td>Thalassemia major</td><td>NCT00007072</td><td>Phase 2</td></tr><tr><td>Resveratrol</td><td>Cardiovas... | <table><tr><td>Curcumin</td><td>Alzheimer disease</td><td>NCT00164749</td><td>Phase 2</td></tr><tr><td>Curcumin</td><td>Psoriasis</td><td>NCT00235625</td><td>Phase 2</td></tr></table> |
e486eb73ab3c9f1af8073c98137d56704984cc8f1bb4ab41727b3d1ba7e3c9c6.png | simple | <table><tr><td>N</td><td>Subfamily</td><td>Unit (bp)</td><td>Arrays</td><td>GC%</td><td>Length (bp)</td><td>Var%</td><td>HOR</td><td>ChrUn</td><td>WGS Chr</td></tr><tr><td>1</td><td>TR-24B-MM</td><td>24</td><td>3</td><td>34.4</td><td>7636</td><td>28</td><td>+</td><td>2</td><td>11</td></tr><tr><td>2</td><td>TR-24A-MM</t... | <table><tr><td>N</td><td>Subfamily</td><td>Unit (bp)</td><td>Arrays</td><td>GC%</td><td>Length (bp)</td><td>Var%</td><td>HOR</td><td>ChrUn</td><td>WGS Chr</td></tr><tr><td>1</td><td>TR-24B-MM</td><td>24</td><td>3</td><td>34.4</td><td>7636</td><td>28</td><td>+</td><td>2</td><td>11</td></tr></table> | <table><tr><td>2</td><td>TR-24A-MM</td><td>24</td><td>2</td><td>45.6</td><td>3540</td><td>22</td><td>+</td><td>2</td><td>Un</td></tr><tr><td>3</td><td>TR-13A-MM</td><td>13</td><td>1</td><td>56.0</td><td>4477</td><td>15</td><td>+</td><td>0</td><td>6</td></tr><tr><td>4</td><td>TR-27B-MM</td><td>27</td><td>1</td><td>63.5<... |
a47eee67d8dfcee4a7e5fb12f4d8c23dc632a4cd087ace5a623ff17bc1219e2b.png | complex | <table><tr><td></td><td colspan="8">Assessment Period</td></tr><tr><td>Measure</td><td>E1</td><td>E2</td><td>2 weeks</td><td>6 weeks</td><td>13-weeks</td><td>6 month</td><td>1 year</td><td>2 years</td></tr><tr><td>Height, weight</td><td colspan="6">Monthly</td><td colspan="2">Every 3 months</td></tr><tr><td>DXA</td><td... | <table><tr><td></td><td colspan="8">Assessment Period</td></tr><tr><td>Measure</td><td>E1</td><td>E2</td><td>2 weeks</td><td>6 weeks</td><td>13-weeks</td><td>6 month</td><td>1 year</td><td>2 years</td></tr><tr><td>Height, weight</td><td colspan="6">Monthly</td><td colspan="2">Every 3 months</td></tr><tr><td>DXA</td><td... | <table><tr><td></td><td colspan="8">Assessment Period</td></tr><tr><td>Measure</td><td>E1</td><td>E2</td><td>2 weeks</td><td>6 weeks</td><td>13-weeks</td><td>6 month</td><td>1 year</td><td>2 years</td></tr><tr><td>EKG</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>PAT</td>... |
b29beb176c27bfaace272f2047c8f99d7a036e27cc2095a9882d3dc15a14bad0.png | simple | <table><tr><td>Patient</td><td>Age/years</td><td>LH (mIU/ml)</td><td>FSH (mIU/ml)</td><td>Prolactin (ng/ml)</td><td>Estradiol (pg/ml)</td><td>Progesterone (ng/ml)</td><td>Testosterone (ng/ml)</td><td>Follicle numbers</td><td>Clinical information</td></tr><tr><td>F1‐II1</td><td>34</td><td>6.58</td><td>17.49↑... | <table><tr><td>Patient</td><td>Age/years</td><td>LH (mIU/ml)</td><td>FSH (mIU/ml)</td><td>Prolactin (ng/ml)</td><td>Estradiol (pg/ml)</td><td>Progesterone (ng/ml)</td><td>Testosterone (ng/ml)</td><td>Follicle numbers</td><td>Clinical information</td></tr><tr><td>F1‐II1</td><td>34</td><td>6.58</td><td>17.49↑</td><td>19.... | <table><tr><td>F2‐II1</td><td>30</td><td>10.33</td><td>17.84↑</td><td>7.16</td><td>42</td><td>0.2</td><td>0.59</td><td>Left: 2, Right: 3</td><td>BPES; Menarche 15 years; irregular cycles</td></tr></table> |
49ea9ef4365ff3202ec00f5edc9816e3d75bcca84693244cf34344152dae4e49.png | complex | <table><tr><td>Survival</td><td colspan="2"><i>MYC</i> CNA<sup>+</sup> and <i>MYC</i>-R<sup>+</sup></td><td colspan="2"><i>MYC</i>-R<sup>+</sup> alone</td><td colspan="2"><i>MYC</i> CNA<sup>+</sup> alone</td></tr><tr><td></td><td>χ<sup>2</sup></td><td><i>P</i> value</td><td>χ<sup>2</sup></td><td><i>P</i> valu... | <table><tr><td>Survival</td><td>MYC CNA+ and MYC-R+</td></tr><tr><td></td><td>χ2</td></tr><tr><td>Overall survival</td><td></td></tr><tr><td>MYC CNA+ and MYC-R+</td><td></td></tr><tr><td>MYC-R+ alone</td><td>2.819</td></tr><tr><td>MYC CNA+ alone</td><td>0.066</td></tr><tr><td>Progression-free survival</td><td></td></tr... | <table><tr><td>MYC CNA+ and MYC-R+</td><td colspan="2">MYC-R+ alone</td><td colspan="2">MYC CNA+ alone</td></tr><tr><td>P value</td><td>χ2</td><td>P value</td><td>χ2</td><td>P value</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>2.819</td><td>0.093</td><td>0.066</td><td>0.797</td></tr><... |
42f87a9ddcb4fa3508a186fc296d600a4c98d199a23ce4adc1f112690aa5cf5c.png | simple | <table><tr><td> </td><td>Before sling</td><td>After sling</td></tr><tr><td>PVDF</td><td>15.4 (±4.3)</td><td>5.6 (±5.9)</td></tr><tr><td>PP</td><td>15.3 (±3.4)</td><td>6.2 (±6.6)</td></tr></table> | <table><tr><td></td><td>Before sling</td><td>After sling</td></tr><tr><td>PVDF</td><td>15.4 (±4.3)</td><td>5.6 (±5.9)</td></tr></table> | <table><tr><td>PP</td><td>15.3 (±3.4)</td><td>6.2 (±6.6)</td></tr></table> |
23422e6a208f0e38e0361f3e3dbe5e426ec16624af3c7a98b020fc747246c64a.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Cases</td><td colspan="2">CD40 mutant expression</td><td rowspan="2"><i>χ</i><sup><i>2</i></sup></td><td rowspan="2"><i>P</i></td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr... | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Cases</td><td colspan="2">CD40 mutant expression</td><td rowspan="2">χ2</td><td rowspan="2">P</td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>58</td><td>33</td><td>25... | <table><tr><td>I and II</td><td>17</td><td>4</td><td>13</td><td rowspan="2">8.774</td><td rowspan="2">0.003a</td></tr><tr><td>III and IV</td><td>61</td><td>39</td><td>22</td></tr></table> |
ad6a355c44a572a4d1b731ce59c01a74f1dfb95b381c65a89028edcc2c3931b3.png | simple | <table><tr><td>Variable</td><td>AHRR <36(n=181)</td><td>AHRR 36–46(n=202)</td><td>AHRR 47–58(n=197)</td><td>AHRR ≥59(n=211)</td><td>p Value(across all groups)</td></tr><tr><td>Age (years)</td><td>71.1 (0.8)</td><td>69.1 (0.8)</td><td>67.8 (0.9)</td><td>63.9 (0.9)</td><td><0.001</td></tr><tr><td>... | <table><tr><td>Variable</td><td>AHRR <36(n=181)</td><td>AHRR 36–46(n=202)</td><td>AHRR 47–58(n=197)</td><td>AHRR ≥59(n=211)</td><td>p Value(across all groups)</td></tr><tr><td>Age (years)</td><td>71.1 (0.8)</td><td>69.1 (0.8)</td><td>67.8 (0.9)</td><td>63.9 (0.9)</td><td><0.001</td></tr><tr><td>Resting heart rate (bpm)... | <table><tr><td>Variable</td><td>AHRR <36(n=181)</td><td>AHRR 36–46(n=202)</td><td>AHRR 47–58(n=197)</td><td>AHRR ≥59(n=211)</td><td>p Value(across all groups)</td></tr><tr><td>Implantable defibrillator (% (n))</td><td>18.2 (33)</td><td>13.4 (27)</td><td>8.6 (17)</td><td>9 (19)</td><td>0.01</td></tr><tr><td>Any atrial f... |
fcf3063253361aa834f0eef4b8c99e254ef59b91fd8d70cd53bf3de52af81d92.png | complex | <table><tr><td>Age (Weeks)</td><td>Sex</td><td>CF1-CD</td><td>CF1-HCD</td><td>DF1-CD</td><td>DF1-HCD</td></tr><tr><td colspan="6">Hepatic TGs content (mg/g tissue)</td></tr><tr><td rowspan="2">5</td><td>Male</td><td>76.4 ± 7</td><td>78 ± 8</td><td>77 ± 6</td><td>79 ± 6</td></tr><tr><td>Female</td><t... | <table><tr><td>Age (Weeks)</td><td>Sex</td><td>CF1-CD</td></tr><tr><td colspan="3">Hepatic TGs content (mg/g tissue)</td></tr><tr><td rowspan="2">5</td><td>Male</td><td>76.4 ± 7</td></tr><tr><td>Female</td><td>74 ± 6</td></tr><tr><td rowspan="2">10</td><td>Male</td><td>81 ± 8</td></tr><tr><td>Female</td><td>78 ± 5</td>... | <table><tr><td>CF1-HCD</td><td>DF1-CD</td><td>DF1-HCD</td></tr><tr><td colspan="3">Hepatic TGs content (mg/g tissue)</td></tr><tr><td>78 ± 8</td><td>77 ± 6</td><td>79 ± 6</td></tr><tr><td>76 ± 5</td><td>75 ± 5</td><td>76 ± 5</td></tr><tr><td>85 ± 8</td><td>87 ± 7</td><td>91 ± 8*</td></tr><tr><td>80 ± 6</td><td>81 ± 5**... |
d447dd12569d7f1a5baafeaa72639586211b8424a9d6d2602ceed85c961f3efe.png | simple | <table><tr><td></td><td>H<sub>2</sub>O</td><td>M9 medium</td><td>LB medium</td><td>10 fold diluted LB medium</td></tr><tr><td>Linear range of adenosine concentrations (mM)</td><td>0.065–10</td><td>0.054–10</td><td>3.2–10</td><td>0.098–10</td></tr><tr><td>Detection limit (mM)</td><td>0.065</td><t... | <table><tr><td></td><td>H2O</td><td>M9 medium</td><td>LB medium</td><td>10 fold diluted LB medium</td></tr><tr><td>Linear range of adenosine concentrations (mM)</td><td>0.065–10</td><td>0.054–10</td><td>3.2–10</td><td>0.098–10</td></tr><tr><td>Detection limit (mM)</td><td>0.065</td><td>0.054</td><td>3.2</td><td>0.098</... | <table><tr><td></td><td>H2O</td><td>M9 medium</td><td>LB medium</td><td>10 fold diluted LB medium</td></tr><tr><td>5</td><td></td><td>8</td><td></td><td>07</td></tr><tr><td>0.075</td><td>1.51</td><td>3.29</td><td></td><td>1.07</td></tr><tr><td>0.1</td><td>1.66</td><td>3.56</td><td></td><td>1.08</td></tr><tr><td>0.25</t... |
f21e8c9dfa50b79992395828391b6d2a9bf9d678e05064319e783724c5ae55f9.png | simple | <table><tr><td>Lottery A</td><td>Lottery B</td><td>Expected value of Lottery A</td><td>Expected value of Lottery B</td></tr><tr><td>10% 100 PLN; 90% 80 PLN</td><td>10% 185 PLN; 90% 5 PLN</td><td>82</td><td>23</td></tr><tr><td>20% 100 PLN; 80% 80 PLN</td><td>20% 185 PLN; 80% 5 PLN</td><td>84</td><td>41</td></tr><tr><td>... | <table><tr><td>Lottery A</td><td>Lottery B</td><td>Expected value of Lottery A</td><td>Expected value of Lottery B</td></tr><tr><td>10% 100 PLN; 90% 80 PLN</td><td>10% 185 PLN; 90% 5 PLN</td><td>82</td><td>23</td></tr><tr><td>20% 100 PLN; 80% 80 PLN</td><td>20% 185 PLN; 80% 5 PLN</td><td>84</td><td>41</td></tr><tr><td>... | <table><tr><td>Lottery A</td><td>Lottery B</td><td>Expected value of Lottery A</td><td>Expected value of Lottery B</td></tr><tr><td>100% 100 PLN; 0% 80 PLN</td><td>100% 185 PLN; 0% 5 PLN</td><td>100</td><td>185</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.